Misplaced Pages

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

Common side effects of antidepressants include dry mouth, weight gain, dizziness, headaches, akathisia, sexual dysfunction, and emotional blunting. There is an increased risk of suicidal thinking and behavior when taken by children, adolescents, and young adults. Discontinuation syndrome, which resembles recurrent depression in the case of the SSRI class, may occur after stopping the intake of any antidepressant, having effects which may be permanent and irreversible.

Research regarding the effectiveness of antidepressants for depression in adults is controversial and has found both benefits and drawbacks. Meanwhile, evidence of benefit in children and adolescents is unclear, even though antidepressant use has considerably increased in children and adolescents in the 2000s. While a 2018 study found that the 21 most commonly prescribed antidepressant medications were slightly more effective than placebos for the short-term (acute) treatments of adults with major depressive disorder, other research has found that the placebo effect may account for most or all of the drugs' observed efficacy.

Research on the effectiveness of antidepressants is generally done on people who have severe symptoms, a population that exhibits much weaker placebo responses, meaning that the results may not be extrapolated to the general population that has not (or has not yet) been diagnosed with anxiety or depression.

Medical uses

Antidepressants are prescribed to treat major depressive disorder (MDD), anxiety disorders, chronic pain, and some addictions. Antidepressants are often used in combination with one another.

Despite its longstanding prominence in pharmaceutical advertising, the idea that low serotonin levels cause depression is not supported by scientific evidence. Proponents of the monoamine hypothesis of depression recommend choosing an antidepressant which impacts the most prominent symptoms. Under this practice, for example, a person with MDD who is also anxious or irritable would be treated with selective serotonin reuptake inhibitors (SSRIs) or norepinephrine reuptake inhibitors, while a person suffering from loss of energy and enjoyment of life would take a norepinephrine–dopamine reuptake inhibitor.

Major depressive disorder

The UK National Institute for Health and Care Excellence (NICE)'s 2022 guidelines indicate that antidepressants should not be routinely used for the initial treatment of mild depression, "unless that is the person's preference". The guidelines recommended that antidepressant treatment be considered:

• For people with a history of moderate or severe depression.
• For people with mild depression that has been present for an extended period.
• As a first-line treatment for moderate to severe depression.
• As a second-line treatment for mild depression that persists after other interventions.

The guidelines further note that in most cases, antidepressants should be used in combination with psychosocial interventions and should be continued for at least six months to reduce the risk of relapse and that SSRIs are typically better tolerated than other antidepressants.

American Psychiatric Association (APA) treatment guidelines recommend that initial treatment be individually tailored based on factors including the severity of symptoms, co-existing disorders, prior treatment experience, and the person's preference. Options may include antidepressants, psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or light therapy. The APA recommends antidepressant medication as an initial treatment choice in people with mild, moderate, or severe major depression, and that should be given to all people with severe depression unless ECT is planned.

Reviews of antidepressants generally find that they benefit adults with depression. On the other hand, some contend that most studies on antidepressant medication are confounded by several biases: the lack of an active placebo, which means that many people in the placebo arm of a double-blind study may deduce that they are not getting any true treatment, thus destroying double-blindness; a short follow up after termination of treatment; non-systematic recording of adverse effects; very strict exclusion criteria in samples of patients; studies being paid for by the industry; selective publication of results. This means that the small beneficial effects that are found may not be statistically significant.

Among the 21 most commonly prescribed antidepressants, the most effective and well-tolerated are escitalopram, paroxetine, sertraline, agomelatine, and mirtazapine. For children and adolescents with moderate to severe depressive disorder, some evidence suggests fluoxetine (either with or without cognitive behavioral therapy) is the best treatment, but more research is needed to be certain. Sertraline, escitalopram, and duloxetine may also help reduce symptoms.

A 2023 systematic review and meta-analysis of randomized controlled trials of antidepressants for major depressive disorder found that the medications provided only small or doubtful benefits in terms of quality of life. Likewise, a 2022 systematic review and meta-analysis of randomized controlled trials of antidepressants for major depressive disorder in children and adolescents found small improvements in quality of life. Quality of life as an outcome measure is often selectively reported in trials of antidepressants.

Anxiety disorders

For children and adolescents, fluvoxamine is effective in treating a range of anxiety disorders. Fluoxetine, sertraline, and paroxetine can also help with managing various forms of anxiety in children and adolescents.

Meta-analyses of published and unpublished trials have found that antidepressants have a placebo-subtracted effect size (standardized mean difference or SMD) in the treatment of anxiety disorders of around 0.3, which equates to a small improvement and is roughly the same magnitude of benefit as their effectiveness in the treatment of depression. The effect size (SMD) for improvement with placebo in trials of antidepressants for anxiety disorders is approximately 1.0, which is a large improvement in terms of effect size definitions. In relation to this, most of the benefit of antidepressants for anxiety disorders is attributable to placebo responses rather than to the effects of the antidepressants themselves.

Generalized anxiety disorder

Antidepressants are recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of generalized anxiety disorder (GAD) that has failed to respond to conservative measures such as education and self-help activities. GAD is a common disorder in which the central feature is excessively worrying about numerous events. Key symptoms include excessive anxiety about events and issues going on around them and difficulty controlling worrisome thoughts that persists for at least 6 months.

Antidepressants provide a modest to moderate reduction in anxiety in GAD. The efficacy of different antidepressants is similar.

Social anxiety disorder

Some antidepressants are used as a treatment for social anxiety disorder, but their efficacy is not entirely convincing, as only a small proportion of antidepressants showed some effectiveness for this condition. Paroxetine was the first drug to be FDA-approved for this disorder. Its efficacy is considered beneficial, although not everyone responds favorably to the drug. Sertraline and fluvoxamine extended-release were later approved for it as well, while escitalopram is used off-label with acceptable efficiency. However, there is not enough evidence to support Citalopram for treating social anxiety disorder, and fluoxetine was no better than a placebo in clinical trials. SSRIs are used as a first-line treatment for social anxiety, but they do not work for everyone. One alternative would be venlafaxine, an SNRI, which has shown benefits for social phobia in five clinical trials against a placebo, while the other SNRIs are not considered particularly useful for this disorder as many of them did not undergo testing for it. As of 2008, it is unclear if duloxetine and desvenlafaxine can provide benefits for people with social anxiety. However, another class of antidepressants called MAOIs are considered effective for social anxiety, but they come with many unwanted side effects and are rarely used. Phenelzine was shown to be a good treatment option, but its use is limited by dietary restrictions. Moclobemide is a RIMA and showed mixed results, but still received approval in some European countries for social anxiety disorder. TCA antidepressants, such as clomipramine and imipramine, are not considered effective for this anxiety disorder in particular. This leaves out SSRIs such as paroxetine, sertraline, and fluvoxamine CR as acceptable and tolerated treatment options for this disorder.

Obsessive–compulsive disorder

SSRIs are a second-line treatment for adult obsessive–compulsive disorder (OCD) with mild functional impairment, and a first-line treatment for those with moderate or severe impairment.

In children, SSRIs are considered as a second-line therapy in those with moderate-to-severe impairment, with close monitoring for psychiatric adverse effects. Sertraline and fluoxetine are effective in treating OCD for children and adolescents.

Clomipramine, a TCA drug, is considered effective and useful for OCD. However, it is used as a second-line treatment because it is less well-tolerated than SSRIs. Despite this, it has not shown superiority to fluvoxamine in trials. All SSRIs can be used effectively for OCD. SNRI use may also be attempted, though no SNRIs have been approved for the treatment of OCD. Despite these treatment options, many patients remain symptomatic after initiating the medication, and less than half achieve remission.

Placebo responses are a large component of the benefit of antidepressants in the treatment of depression and anxiety. However, placebo responses with antidepressants are lower in magnitude in the treatment of OCD compared to depression and anxiety. A 2019 meta-analysis found placebo improvement effect sizes (SMD) of about 1.2 for depression, 1.0 for anxiety disorders, and 0.6 for OCD with antidepressants.

Post–traumatic stress disorder

Antidepressants are one of the treatment options for PTSD. However, their efficacy is not well established. Paroxetine and sertraline have been FDA approved for the treatment of PTSD. Paroxetine has slightly higher response and remission rates than sertraline for this condition. However, neither drug is considered very helpful for a broad patient demographic. Fluoxetine and venlafaxine are used off-label. Fluoxetine has produced unsatisfactory mixed results. Venlafaxine showed response rates of 78%, which is significantly higher than what paroxetine and sertraline achieved. However, it did not address as many symptoms of PTSD as paroxetine and sertraline, in part due to the fact that venlafaxine is an SNRI. This class of drugs inhibits the reuptake of norepinephrine, which may cause anxiety in some patients. Fluvoxamine, escitalopram, and citalopram were not well-tested for this disorder. MAOIs, while some of them may be helpful, are not used much because of their unwanted side effects. This leaves paroxetine and sertraline as acceptable treatment options for some people, although more effective antidepressants are needed.

Panic disorder

Panic disorder is treated relatively well with medications compared to other disorders. Several classes of antidepressants have shown efficacy for this disorder, with SSRIs and SNRIs used first-line. Paroxetine, sertraline, and fluoxetine are FDA-approved for panic disorder, while fluvoxamine, escitalopram, and citalopram are also considered effective for them. SNRI venlafaxine is also approved for this condition. Unlike social anxiety and PTSD, some TCAs antidepressants, like clomipramine and imipramine, have shown efficacy for panic disorder. Moreover, the MAOI phenelzine is also considered useful. Panic disorder has many drugs for its treatment. However, the starting dose must be lower than the one used for major depressive disorder because people have reported an increase in anxiety as a result of starting the medication. In conclusion, while panic disorder's treatment options seem acceptable and useful for this condition, many people are still symptomatic after treatment with residual symptoms.

Eating disorders

Antidepressants are recommended as an alternative or additional first step to self-help programs in the treatment of bulimia nervosa. SSRIs (fluoxetine in particular) are preferred over other antidepressants due to their acceptability, tolerability, and superior reduction of symptoms in short-term trials. Long-term efficacy remains poorly characterized. Bupropion is not recommended for the treatment of eating disorders, due to an increased risk of seizure.

Similar recommendations apply to binge eating disorder. SSRIs provide short-term reductions in binge eating behavior, but have not been associated with significant weight loss.

Clinical trials have generated mostly negative results for the use of SSRIs in the treatment of anorexia nervosa. Treatment guidelines from the National Institute of Health and Care Excellence (NICE) recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association (APA) note that SSRIs confer no advantage regarding weight gain, but may be used for the treatment of co-existing depressive, anxiety, or obsessive–compulsive disorders.

Pain

Fibromyalgia

A 2012 meta-analysis concluded that antidepressant treatment favorably affects pain, health-related quality of life, depression, and sleep in fibromyalgia syndrome. Tricyclics appear to be the most effective class, with moderate effects on pain and sleep, and small effects on fatigue and health-related quality of life. The fraction of people experiencing a 30% pain reduction on tricyclics was 48%, versus 28% on placebo. For SSRIs and SNRIs, the fractions of people experiencing a 30% pain reduction were 36% (20% in the placebo comparator arms) and 42% (32% in the corresponding placebo comparator arms) respectively. Discontinuation of treatment due to side effects was common. Antidepressants including amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, and pirlindole are recommended by the European League Against Rheumatism (EULAR) for the treatment of fibromyalgia based on "limited evidence".

Neuropathic pain

A 2014 meta-analysis from the Cochrane Collaboration found the antidepressant duloxetine to be effective for the treatment of pain resulting from diabetic neuropathy. The same group reviewed data for amitriptyline in the treatment of neuropathic pain and found limited useful randomized clinical trial data. They concluded that the long history of successful use in the community for the treatment of fibromyalgia and neuropathic pain justified its continued use. The group was concerned about the potential overestimation of the amount of pain relief provided by amitriptyline, and highlighted that only a small number of people will experience significant pain relief by taking this medication.

Other uses

Antidepressants may be modestly helpful for treating people who have both depression and alcohol dependence, however, the evidence supporting this association is of low quality. Bupropion is used to help people stop smoking. Antidepressants are also used to control some symptoms of narcolepsy. Antidepressants may be used to relieve pain in people with active rheumatoid arthritis. However, further research is required. Antidepressants have been shown to be superior to placebo in treating depression in individuals with physical illness, although reporting bias may have exaggerated this finding. Antidepressants have been shown to improve some parts of cognitive functioning for depressed users, such as memory, attention, and processing speed.

Certain antidepressants acting as serotonin 5-HT_2A receptor antagonists, such as trazodone and mirtazapine, have been used as hallucinogen antidotes or "trip killers" to block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).

Limitations and strategies

Among individuals treated with a given antidepressant, between 30% and 50% do not show a response. Approximately one-third of people achieve a full remission, one-third experience a response, and one-third are non-responders. Partial remission is characterized by the presence of poorly defined residual symptoms. These symptoms typically include depressed mood, anxiety, sleep disturbance, fatigue, and diminished interest or pleasure. It is currently unclear which factors predict partial remission. However, it is clear that residual symptoms are powerful predictors of relapse, with relapse rates three to six times higher in people with residual symptoms than in those, who experience full remission. In addition, antidepressant drugs tend to lose efficacy throughout long-term maintenance therapy. According to data from the Centers for Disease Control and Prevention, less than one-third of Americans taking one antidepressant medication have seen a mental health professional in the previous year. Several strategies are used in clinical practice to try to overcome these limits and variations. They include switching medication, augmentation, and combination.

There is controversy amongst researchers regarding the efficacy and risk-benefit ratio of antidepressants. Although antidepressants consistently out-perform a placebo in meta-analyses, the difference is modest and it is not clear that their statistical superiority results in clinical efficacy. The aggregate effect of antidepressants typically results in changes below the threshold of clinical significance on depression rating scales. Proponents of antidepressants counter that the most common scale, the HDRS, is not suitable for assessing drug action, that the threshold for clinical significance is arbitrary, and that antidepressants consistently result in significantly raised scores on the mood item of the scale. Assessments of antidepressants using alternative, more sensitive scales, such as the MADRS, do not result in marked difference from the HDRS and likewise only find a marginal clinical benefit. Another hypothesis proposed to explain the poor performance of antidepressants in clinical trials is a high treatment response heterogeneity. Some patients, that differ strongly in their response to antidepressants, could influence the average response, while the heterogeneity could itself be obscured by the averaging. Studies have not supported this hypothesis, but it is very difficult to measure treatment effect heterogeneity. Poor and complex clinical trial design might also account for the small effects seen for antidepressants. The randomized controlled trials used to approve drugs are short, and may not capture the full effect of antidepressants. Additionally, the placebo effect might be inflated in these trials by frequent clinical consultation, lowering the comparative performance of antidepressants. Critics agree that current clinical trials are poorly-designed, which limits the knowledge on antidepressants. More naturalistic studies, such as STAR*D, have produced results, which suggest that antidepressants may be less effective in clinical practice than in randomized controlled trials.

Critics of antidepressants maintain that the superiority of antidepressants over placebo is the result of systemic flaws in clinical trials and the research literature. Trials conducted with industry involvement tend to produce more favorable results, and accordingly many of the trials included in meta-analyses are at high risk of bias. Additionally, meta-analyses co-authored by industry employees find more favorable results for antidepressants. The results of antidepressant trials are significantly more likely to be published if they are favorable, and unfavorable results are very often left unpublished or misreported, a phenomenon called publication bias or selective publication. Although this issue has diminished with time, it remains an obstacle to accurately assessing the efficacy of antidepressants. Misreporting of clinical trial outcomes and of serious adverse events, such as suicide, is common. Ghostwriting of antidepressant trials is widespread, a practice in which prominent researchers, or so-called key opinion leaders, attach their names to studies actually written by pharmaceutical company employees or consultants. A particular concern is that the psychoactive effects of antidepressants may lead to the unblinding of participants or researchers, enhancing the placebo effect and biasing results. Some have therefore maintained that antidepressants may only be active placebos. When these and other flaws in the research literature are not taken into account, meta-analyses may find inflated results on the basis of poor evidence.

Critics contend that antidepressants have not been proven sufficiently effective by RCTs or in clinical practice and that the widespread use of antidepressants is not evidence-based. They also note that adverse effects, including withdrawal difficulties, are likely underreported, skewing clinicians' ability to make risk-benefit judgements. Accordingly, they believe antidepressants are overused, particularly for non-severe depression and conditions in which they are not indicated. Critics charge that the widespread use and public acceptance of antidepressants is the result of pharmaceutical advertising, research manipulation, and misinformation.

Current mainstream psychiatric opinion recognizes the limitations of antidepressants but recommends their use in adults with more severe depression as a first-line treatment.

Switching antidepressants

The American Psychiatric Association 2000 Practice Guideline advises that where no response is achieved within the following six to eight weeks of treatment with an antidepressant, switch to an antidepressant in the same class, and then to a different class. A 2006 meta-analysis review found wide variation in the findings of prior studies: for people who had failed to respond to an SSRI antidepressant, between 12% and 86% showed a response to a new drug. However, the more antidepressants an individual had previously tried, the less likely they were to benefit from a new antidepressant trial. However, a later meta-analysis found no difference between switching to a new drug and staying on the old medication: although 34% of treatment-resistant people responded when switched to the new drug, 40% responded without being switched.

Augmentation and combination

For a partial response, the American Psychiatric Association (APA) guidelines suggest augmentation or adding a drug from a different class. These include lithium and thyroid augmentation, dopamine agonists, sex steroids, NRIs, glucocorticoid-specific agents, or the newer anticonvulsants.

A combination strategy involves adding another antidepressant, usually from a different class to affect other mechanisms. Although this may be used in clinical practice, there is little evidence for the relative efficacy or adverse effects of this strategy. Other tests conducted include the use of psychostimulants as an augmentation therapy. Several studies have shown the efficacy of combining modafinil for treatment-resistant people. It has been used to help combat SSRI-associated fatigue.

Long-term use and stopping

The effects of antidepressants typically do not continue once the course of medication ends. This results in a high rate of relapse. In 2003, a meta-analysis found that 18% of people who had responded to an antidepressant relapsed while still taking it, compared to 41% whose antidepressant was switched for a placebo.

A gradual loss of therapeutic benefit occurs in a minority of people during the course of treatment. A strategy involving the use of pharmacotherapy in the treatment of the acute episode, followed by psychotherapy in its residual phase, has been suggested by some studies. For patients who wish to stop their antidepressants, engaging in brief psychological interventions such as Preventive Cognitive Therapy or mindfulness-based cognitive therapy while tapering down has been found to diminish the risk for relapse.

Adverse effects

Antidepressants can cause various adverse effects, depending on the individual and the drug in question.

Almost any medication involved with serotonin regulation has the potential to cause serotonin toxicity (also known as serotonin syndrome) – an excess of serotonin that can induce mania, restlessness, agitation, emotional lability, insomnia, and confusion as its primary symptoms. Although the condition is serious, it is not particularly common, generally only appearing at high doses or while on other medications. Assuming proper medical intervention has been taken (within about 24 hours) it is rarely fatal. Antidepressants appear to increase the risk of diabetes by about 1.3-fold.

MAOIs tend to have pronounced (sometimes fatal) interactions with a wide variety of medications and over-the-counter drugs. If taken with foods that contain very high levels of tyramine (e.g., mature cheese, cured meats, or yeast extracts), they may cause a potentially lethal hypertensive crisis. At lower doses, the person may only experience a headache due to an increase in blood pressure.

In response to these adverse effects, a different type of MAOI, the class of reversible inhibitor of monoamine oxidase A (RIMA), has been developed. The primary advantage of RIMAs is that they do not require the person to follow a special diet while being purportedly effective as SSRIs and tricyclics in treating depressive disorders.

Tricyclics and SSRI can cause the so-called drug-induced QT prolongation, especially in older adults; this condition can degenerate into a specific type of abnormal heart rhythm called Torsades de points, which can potentially lead to sudden cardiac arrest.

Some antidepressants are also believed to increase thoughts of suicidal ideation.

Antidepressants have been associated with an increased risk of dementia in older adults.

Researchers have developed a tool that allows people to rate their concern about common side effects of antidepressants. The tool ranks potential treatment options in a visual display that highlights the drugs with side effects of least concern to an individual.

Pregnancy

SSRI use in pregnancy has been associated with a variety of risks with varying degrees of proof of causation. As depression is independently associated with negative pregnancy outcomes, determining the extent to which observed associations between antidepressant use and specific adverse outcomes reflect a causative relationship has been difficult in some cases. In other cases, the attribution of adverse outcomes to antidepressant exposure seems fairly clear.

SSRI use in pregnancy is associated with an increased risk of spontaneous abortion of about 1.7-fold, and is associated with preterm birth and low birth weight.

A systematic review of the risk of major birth defects in antidepressant-exposed pregnancies found a small increase (3% to 24%) in the risk of major malformations and a risk of cardiovascular birth defects that did not differ from non-exposed pregnancies. A study of fluoxetine-exposed pregnancies found a 12% increase in the risk of major malformations that did not reach statistical significance. Other studies have found an increased risk of cardiovascular birth defects among depressed mothers not undergoing SSRI treatment, suggesting the possibility of ascertainment bias, e.g. that worried mothers may pursue more aggressive testing of their infants. Another study found no increase in cardiovascular birth defects and a 27% increased risk of major malformations in SSRI exposed pregnancies. The FDA advises for the risk of birth defects with the use of paroxetine and the MAOI should be avoided.

A 2013 systematic review and meta-analysis found that antidepressant use during pregnancy was statistically significantly associated with some pregnancy outcomes, such as gestational age and preterm birth, but not with other outcomes. The same review cautioned that because differences between the exposed and unexposed groups were small, it was doubtful whether they were clinically significant.

A neonate (infant less than 28 days old) may experience a withdrawal syndrome from abrupt discontinuation of the antidepressant at birth. Antidepressants can be present in varying amounts in breast milk, but their effects on infants are currently unknown.

Moreover, SSRIs inhibit nitric oxide synthesis, which plays an important role in setting the vascular tone. Several studies have pointed to an increased risk of prematurity associated with SSRI use, and this association may be due to an increased risk of pre-eclampsia during pregnancy.

Antidepressant-induced mania

Another possible problem with antidepressants is the chance of antidepressant-induced mania or hypomania in people with or without a diagnosis of bipolar disorder. Many cases of bipolar depression are very similar to those of unipolar depression. Therefore, the person can be misdiagnosed with unipolar depression and be given antidepressants. Studies have shown that antidepressant-induced mania can occur in 20–40% of people with bipolar disorder. For bipolar depression, antidepressants (most frequently SSRIs) can exacerbate or trigger symptoms of hypomania and mania. Bupropion has been associated with a lower risk of mood switch than other antidepressants.

Suicide

Studies have shown that the use of antidepressants is correlated with an increased risk of suicidal behavior and thinking (suicidality) in those aged under 25 years old. This problem has been serious enough to warrant government intervention by the US Food and Drug Administration (FDA) to warn of the increased risk of suicidality during antidepressant treatment. According to the FDA, the heightened risk of suicidality occurs within the first one to two months of treatment. The National Institute for Health and Care Excellence (NICE) places the excess risk in the "early stages of treatment". A meta-analysis suggests that the relationship between antidepressant use and suicidal behavior or thoughts is age-dependent. Compared with placebo, the use of antidepressants is associated with an increase in suicidal behavior or thoughts among those 25 years old or younger (OR=1.62). A review of RCTs and epidemiological studies by Healy and Whitaker found an increase in suicidal acts by a factor of 2.4. There is no effect or possibly a mild protective effect among those aged 25 to 64 (OR=0.79). Antidepressant treatment has a protective effect against suicidality among those aged 65 and over (OR=0.37).

Sexual dysfunction

Sexual side effects are also common with SSRIs, such as loss of sexual drive, failure to reach orgasm, and erectile dysfunction. Although usually reversible, these sexual side-effects can, in rare cases, continue after the drug has been completely withdrawn.

In a study of 1,022 outpatients, overall sexual dysfunction with all antidepressants averaged 59.1% with SSRI values between 57% and 73%, mirtazapine 24%, nefazodone 8%, amineptine 7%, and moclobemide 4%. Moclobemide, a selective reversible MAO-A inhibitor, does not cause sexual dysfunction and can lead to an improvement in all aspects of sexual function.

Biochemical mechanisms suggested as causative include increased serotonin, particularly affecting 5-HT₂ and 5-HT₃ receptors; decreased dopamine; decreased norepinephrine; blockade of cholinergic and α₁adrenergic receptors; inhibition of nitric oxide synthetase; and elevation of prolactin levels. Mirtazapine is reported to have fewer sexual side effects, most likely because it antagonizes 5-HT₂ and 5-HT₃ receptors and may, in some cases, reverse sexual dysfunction induced by SSRIs by the same mechanism.

Bupropion, a weak NDRI and nicotinic antagonist, may be useful in treating reduced libido as a result of SSRI treatment.

Emotional blunting

Certain antidepressants may cause emotional blunting, characterized by a reduced intensity of both positive and negative emotions as well as symptoms of apathy, indifference, and amotivation. It may be experienced as either beneficial or detrimental depending on the situation. This side effect has been particularly associated with serotonergic antidepressants like SSRIs and SNRIs but may be less with atypical antidepressants like bupropion, agomelatine, and vortioxetine. Higher doses of antidepressants seem to be more likely to produce emotional blunting than lower doses. Emotional blunting can be decreased by reducing dosage, discontinuing the medication, or switching to a different antidepressant that may have less propensity for causing this side effect.

Changes in weight

Changes in appetite or weight are common among antidepressants but are largely drug-dependent and related to which neurotransmitters they affect. Mirtazapine and paroxetine, for example, may be associated with weight gain and/or increased appetite, while others (such as bupropion and venlafaxine) achieve the opposite effect.

The antihistaminic properties of certain TCA- and TeCA-class antidepressants have been shown to contribute to the common side effects of increased appetite and weight gain associated with these classes of medication.

Bone loss

A 2021 nationwide cohort study in South Korea observed a link between SSRI use and bone loss, particularly in recent users. The study also stressed the need of further research to better understand these effects. A 2012 review found that SSRIs along with tricyclic antidepressants were associated with a significant increase in the risk of osteoporotic fractures, peaking in the months after initiation, and moving back towards baseline during the year after treatment was stopped. These effects exhibited a dose–response relationship within SSRIs which varied between different drugs of that class. A 2018 meta-analysis of 11 small studies found a reduction in bone density of the lumbar spine in SSRI users which affected older people the most.

Risk of death

A 2017 meta-analysis found that antidepressants were associated with a significantly increased risk of death (+33%) and new cardiovascular complications (+14%) in the general population. Conversely, risks were not greater in people with existing cardiovascular disease.

Discontinuation syndrome

Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication. The symptoms may include flu-like symptoms, trouble sleeping, nausea, poor balance, sensory changes, and anxiety. The problem usually begins within three days and may last for several months. Rarely psychosis may occur.

A discontinuation syndrome can occur after stopping any antidepressant including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). The risk is greater among those who have taken the medication for longer and when the medication in question has a short half-life. The underlying reason for its occurrence is unclear. The diagnosis is based on the symptoms.

Methods of prevention include gradually decreasing the dose among those who wish to stop, though it is possible for symptoms to occur with tapering. Treatment may include restarting the medication and slowly decreasing the dose. People may also be switched to the long-acting antidepressant fluoxetine, which can then be gradually decreased.

Approximately 20–50% of people who suddenly stop an antidepressant develop an antidepressant discontinuation syndrome. The condition is generally not serious. Though about half of people with symptoms describe them as severe. Some restart antidepressants due to the severity of the symptoms.

Pharmacology

Antidepressants act via a large number of different mechanisms of action. This includes serotonin reuptake inhibition (SSRIs, SNRIs, TCAs, vilazodone, vortioxetine), norepinephrine reuptake inhibition (NRIs, SNRIs, TCAs), dopamine reuptake inhibition (bupropion, amineptine, nomifensine), direct modulation of monoamine receptors (vilazodone, vortioxetine, SARIs, agomelatine, TCAs, TeCAs, antipsychotics), monoamine oxidase inhibition (MAOIs), and NMDA receptor antagonism (ketamine, esketamine, dextromethorphan), among others (e.g., brexanolone, tianeptine). Some antidepressants also have additional actions, like sigma receptor modulation (certain SSRIs, TCAs, dextromethorphan) and antagonism of histamine H₁ and muscarinic acetylcholine receptors (TCAs, TeCAs).

The earliest and most widely known scientific theory of antidepressant action is the monoamine hypothesis, which can be traced back to the 1950s and 1960s. This theory states that depression is due to an imbalance, most often a deficiency, of the monoamine neurotransmitters, namely serotonin, norepinephrine, and/or dopamine. However, serotonin in particular has been implicated, as in the serotonin hypothesis of depression. The monoamine hypothesis was originally proposed based on observations that reserpine, a drug which depletes the monoamine neurotransmitters, produced depressive effects in people, and that certain hydrazine antituberculosis agents like iproniazid, which prevent the breakdown of monoamine neurotransmitters, produced apparent antidepressant effects. Most currently marketed antidepressants, which are monoaminergic in their actions, are theoretically consistent with the monoamine hypothesis. Despite the widespread nature of the monoamine hypothesis, it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, many people with depression do not respond to monoaminergic antidepressants. A number of alternative hypotheses have been proposed, including hypotheses involving glutamate, neurogenesis, epigenetics, cortisol hypersecretion, and inflammation, among others.

In 2022, a major systematic umbrella review by Joanna Moncrieff and colleagues showed that the serotonin theory of depression was not supported by evidence from a wide variety of areas. The authors concluded that there is no association between serotonin and depression, and that there is no evidence that strongly supports the theory that depression is caused by low serotonin activity or concentrations. Other literature had described the lack of support for the theory previously. In many of the expert responses to the review, it was stated that the monoamine hypothesis had already long been abandoned by psychiatry. This is in spite of about 90% of the general public in Western countries believing the theory to be true and many in the field of psychiatry continuing to promote the theory up to recent times. In addition to the serotonin umbrella review, reviews have found that reserpine, a drug that depletes the monoamine neurotransmitters—including serotonin, norepinephrine, and dopamine—shows no consistent evidence of producing depressive effects. Instead, findings of reserpine and mood are highly mixed, with similar proportions of studies finding that it has no influence on mood, produces depressive effects, or actually has antidepressant effects. In relation to this, the general monoamine hypothesis, as opposed to only the serotonin theory of depression, likewise does not appear to be well-supported by evidence.

The serotonin and monoamine hypotheses of depression have been heavily promoted by the pharmaceutical industry (e.g., in advertisements) and by the psychiatric profession at large despite the lack of evidence in support of them. In the case of the pharmaceutical industry, this can be attributed to obvious financial incentives, with the theory creating a bias against non-pharmacological treatments for depression.

An alternative theory for antidepressant action proposed by certain academics such as Irving Kirsch and Joanna Moncrieff is that they work largely or entirely via placebo mechanisms. This is supported by meta-analyses of randomized controlled trials of antidepressants for depression, which consistently show that placebo groups in trials improve about 80 to 90% as much as antidepressant groups on average and that antidepressants are only marginally more effective for depression than placebos. The difference between antidepressants and placebo corresponds to an effect size (SMD) of about 0.3, which in turn equates to about a 2- to 3-point additional improvement on the 0–52-point (HRSD) and 0–60-point (MADRS) depression rating scales used in trials. Differences in effectiveness between different antidepressants are small and not clinically meaningful. The small advantage of antidepressants over placebo is often statistically significant and is the basis for their regulatory approval, but is sufficiently modest that its clinical significance is doubtful. Moreover, the small advantage of antidepressants over placebo may simply be a methodological artifact caused by unblinding due to the psychoactive effects and side effects of antidepressants, in turn resulting in enhanced placebo effects and apparent antidepressant efficacy. Placebos have been found to modify the activity of several brain regions and to increase levels of dopamine and endogenous opioids in the reward pathways. It has been argued by Kirsch that although antidepressants may be used efficaciously for depression as active placebos, they are limited by significant pharmacological side effects and risks, and therefore non-pharmacological therapies, such as psychotherapy and lifestyle changes, which can have similar efficacy to antidepressants but do not have their adverse effects, ought to be preferred as treatments in people with depression.

The placebo response, or the improvement in scores in the placebo group in clinical trials, is not only due to the placebo effect, but is also due to other phenomena such as spontaneous remission and regression to the mean. Depression tends to have an episodic course, with people eventually recovering even with no medical intervention, and people tend to seek treatment, as well as enroll in clinical trials, when they are feeling their worst. In meta-analyses of trials of depression therapies, Kirsch estimated based on improvement in untreated waiting-list controls that spontaneous remission and regression to the mean only account for about 25% of the improvement in depression scores with antidepressant therapy. However, another academic, Michael P. Hengartner, has argued and presented evidence that spontaneous remission and regression to the mean might actually account for most of the improvement in depression scores with antidepressants, and that the substantial placebo effect observed in clinical trials might largely be a methodological artifact. This suggests that antidepressants may be associated with much less genuine treatment benefit, whether due to the placebo effect or to the antidepressant itself, than has been traditionally assumed.

Types

Selective serotonin reuptake inhibitors

Selective serotonin reuptake inhibitors (SSRIs) are believed to increase the extracellular level of the neurotransmitter serotonin by limiting its reabsorption into the presynaptic cell, increasing the level of serotonin in the synaptic cleft available to bind to the postsynaptic receptor. They have varying degrees of selectivity for the other monoamine transporters, with pure SSRIs having only weak affinity for the norepinephrine and dopamine transporters.

SSRIs are the most widely prescribed antidepressants in many countries. The efficacy of SSRIs in mild or moderate cases of depression has been disputed.

Serotonin–norepinephrine reuptake inhibitors

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are potent inhibitors of the reuptake of serotonin and norepinephrine. These neurotransmitters are known to play an important role in mood. SNRIs can be contrasted with the more widely used selective serotonin reuptake inhibitors (SSRIs), which act mostly upon serotonin alone.

The human serotonin transporter (SERT) and norepinephrine transporter (NET) are membrane proteins that are responsible for the reuptake of serotonin and norepinephrine. Balanced dual inhibition of monoamine reuptake may offer advantages over other antidepressants drugs by treating a wider range of symptoms.

SNRIs are sometimes also used to treat anxiety disorders, obsessive–compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic pain, and fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms.

Serotonin modulators and stimulators

Serotonin modulator and stimulators (SMSs), sometimes referred to more simply as "serotonin modulators", are a type of drug with a multimodal action specific to the serotonin neurotransmitter system. To be precise, SMSs simultaneously modulate one or more serotonin receptors and inhibit the reuptake of serotonin. The term was coined in reference to the mechanism of action of the serotonergic antidepressant vortioxetine, which acts as a serotonin reuptake inhibitor (SRI), a partial agonist of the 5-HT_1A receptor, and antagonist of the 5-HT₃ and 5-HT₇ receptors. However, it can also technically be applied to vilazodone, which is an antidepressant as well and acts as an SRI and 5-HT_1A receptor partial agonist.

An alternative term is serotonin partial agonist/reuptake inhibitor (SPARI), which can be applied only to vilazodone.

Serotonin antagonists and reuptake inhibitors

Serotonin antagonist and reuptake inhibitors (SARIs) while mainly used as antidepressants are also anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT_2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also act as α₁-adrenergic receptor antagonists. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds. They include trazodone and nefazodone.

Tricyclic antidepressants

The majority of the tricyclic antidepressants (TCAs) act primarily as serotonin–norepinephrine reuptake inhibitors (SNRIs) by blocking the serotonin transporter (SERT) and the norepinephrine transporter (NET), respectively, which results in an elevation of the synaptic concentrations of these neurotransmitters, and therefore an enhancement of neurotransmission. Notably, with the sole exception of amineptine, the TCAs have weak affinity for the dopamine transporter (DAT), and therefore have low efficacy as dopamine reuptake inhibitors (DRIs).

Although TCAs are sometimes prescribed for depressive disorders, they have been largely replaced in clinical use in most parts of the world by newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and norepinephrine reuptake inhibitors (NRIs). Adverse effects have been found to be of a similar level between TCAs and SSRIs.

Tetracyclic antidepressants

Tetracyclic antidepressants (TeCAs) are a class of antidepressants that were first introduced in the 1970s. They are named after their chemical structure, which contains four rings of atoms, and are closely related to tricyclic antidepressants (TCAs), which contain three rings of atoms.

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors (MAOIs) are chemicals that inhibit the activity of the monoamine oxidase enzyme family. They have a long history of use as medications prescribed for the treatment of depression. They are particularly effective in treating atypical depression. They are also used in the treatment of Parkinson's disease and several other disorders.

Because of potentially lethal dietary and drug interactions, MAOIs have historically been reserved as a last line of treatment, used only when other classes of antidepressant drugs (for example selective serotonin reuptake inhibitors and tricyclic antidepressants) have failed.

MAOIs have been found to be effective in the treatment of panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, and post-traumatic stress disorder, as well as borderline personality disorder. MAOIs appear to be particularly effective in the management of bipolar depression according to a retrospective-analysis. There are reports of MAOI efficacy in obsessive–compulsive disorder (OCD), trichotillomania, dysmorphophobia, and avoidant personality disorder, but these reports are from uncontrolled case reports.

MAOIs can also be used in the treatment of Parkinson's disease by targeting MAO-B in particular (therefore affecting dopaminergic neurons), as well as providing an alternative for migraine prophylaxis. Inhibition of both MAO-A and MAO-B is used in the treatment of clinical depression and anxiety disorders.

NMDA receptor antagonists

NMDA receptor antagonists like ketamine and esketamine are rapid-acting antidepressants and seem to work via blockade of the ionotropic glutamate NMDA receptor. Other NMDA antagonists may also play a role in treating depression. The combination medication dextromethorphan/bupropion (Auvelity), which contains the NMDA receptor antagonist dextromethorphan, was approved in the United States in 2022 for treating major depressive disorder.

Others

See the list of antidepressants and management of depression for other drugs that are not specifically characterized.

Adjuncts

Adjunct medications are an umbrella category of substances that increase the potency or "enhance" antidepressants. They work by affecting variables very close to the antidepressant, sometimes affecting a completely different mechanism of action. This may be attempted when depression treatments have not been successful in the past.

Common types of adjunct medication techniques generally fall into the following categories:

• Two or more antidepressants taken together, from either the same or different classes (affecting the same area of the brain, often at a much higher level).
• An antipsychotic combined with an antidepressant, particularly atypical antipsychotics such as aripiprazole (Abilify), quetiapine (Seroquel), olanzapine (Zyprexa), and risperidone (Risperdal).

It is unknown if undergoing psychological therapy at the same time as taking anti-depressants enhances the anti-depressive effect of the medication.

Less common adjuncts

Lithium has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone. Furthermore, Lithium dramatically decreases the suicide risk in recurrent depression. There is some evidence for the addition of a thyroid hormone, triiodothyronine, in patients with normal thyroid function.

Psychopharmacologists have also tried adding a stimulant, in particular, D-amphetamine. However, the use of stimulants in cases of treatment-resistant depression is relatively controversial. A review article published in 2007 found psychostimulants may be effective in treatment-resistant depression with concomitant antidepressant therapy, but a more certain conclusion could not be drawn due to substantial deficiencies in the studies available for consideration, and the somewhat contradictory nature of their results.

History

The idea of an antidepressant, if melancholy is thought synonymous with depression, existed at least as early as the 1599 pamphlet A pil to purge melancholie or, A preprative to a pvrgation: or, Topping, copping, and capping: take either or whether: or, Mash them, and squash them, and dash them, and diddle come derrie come daw them, all together... Thomas d'Urfey's Wit and Mirth: Or Pills to Purge Melancholy, the title of a large collection of songs, was published between 1698 and 1720.

Before the 1950s, opioids and amphetamines were commonly used as antidepressants. Amphetamine has been described as the first antidepressant. Use of opioids and amphetamines for depression was later restricted due to their addictive nature and side effects. Extracts from the herb St John's wort have been used as a "nerve tonic" to alleviate depression.

St John's wort fell out of favor in most countries through the 19th and 20th centuries, except in Germany, where Hypericum extracts were eventually licensed, packaged, and prescribed. Small-scale efficacy trials were carried out in the 1970s and 1980s, and attention grew in the 1990s following a meta-analysis. It remains an over-the-counter (OTC) supplement in most countries. Lead contamination associated with its usage has been seen as concerning, as lead levels in women in the United States taking St. John's wort are elevated by about 20% on average. Research continues to investigate its active component hyperforin, and to further understand its mode of action.

Isoniazid, iproniazid, and imipramine

In 1951, Irving Selikoff and Edward H. Robitzek, working out of Sea View Hospital on Staten Island, began clinical trials on two new anti-tuberculosis agents developed by Hoffman-LaRoche, isoniazid, and iproniazid. Only patients with a poor prognosis were initially treated. Nevertheless, their condition improved dramatically. Selikoff and Robitzek noted "a subtle general stimulation ... the patients exhibited renewed vigor and indeed this occasionally served to introduce disciplinary problems." The promise of a cure for tuberculosis in the Sea View Hospital trials was excitedly discussed in the mainstream press.

In 1952, learning of the stimulating side effects of isoniazid, the Cincinnati psychiatrist Max Lurie tried it on his patients. In the following year, he and Harry Salzer reported that isoniazid improved depression in two-thirds of their patients, so they then coined the term antidepressant to refer to its action. A similar incident took place in Paris, where Jean Delay, head of psychiatry at Sainte-Anne Hospital, heard of this effect from his pulmonology colleagues at Cochin Hospital. In 1952 (before Lurie and Salzer), Delay, with the resident Jean-Francois Buisson, reported the positive effect of isoniazid on depressed patients. The mode of antidepressant action of isoniazid is still unclear. It is speculated that its effect is due to the inhibition of diamine oxidase, coupled with a weak inhibition of monoamine oxidase A.

Selikoff and Robitzek also experimented with another anti-tuberculosis drug, iproniazid; it showed a greater psychostimulant effect, but more pronounced toxicity. Later, Jackson Smith, Gordon Kamman, George E. Crane, and Frank Ayd, described the psychiatric applications of iproniazid. Ernst Zeller found iproniazid to be a potent monoamine oxidase inhibitor. Nevertheless, iproniazid remained relatively obscure until Nathan S. Kline, the influential head of research at Rockland State Hospital, began to popularize it in the medical and popular press as a "psychic energizer". Roche put a significant marketing effort behind iproniazid. Its sales grew until it was recalled in 1961, due to reports of lethal hepatotoxicity.

The antidepressant effect of a tricyclic antidepressant, a three-ringed compound, was first discovered in 1957 by Roland Kuhn in a Swiss psychiatric hospital. Antihistamine derivatives were used to treat surgical shock and later as neuroleptics. Although in 1955, reserpine was shown to be more effective than a placebo in alleviating anxious depression, neuroleptics were being developed as sedatives and antipsychotics.

Attempting to improve the effectiveness of chlorpromazine, Kuhn — in conjunction with the Geigy Pharmaceutical Company — discovered the compound "G 22355", later renamed imipramine. Imipramine had a beneficial effect on patients with depression who showed mental and motor retardation. Kuhn described his new compound as a "thymoleptic" "taking hold of the emotions," in contrast with neuroleptics, "taking hold of the nerves" in 1955–56. These gradually became established, resulting in the patent and manufacture in the US in 1951 by Häfliger and SchinderA.

Antidepressants became prescription drugs in the 1950s. It was estimated that no more than fifty to one hundred individuals per million had the kind of depression that these new drugs would treat, and pharmaceutical companies were not enthusiastic about marketing for this small market. Sales through the 1960s remained poor compared to the sales of tranquilizers, which were being marketed for different uses. Imipramine remained in common use and numerous successors were introduced. The use of monoamine oxidase inhibitors (MAOI) increased after the development and introduction of "reversible" forms affecting only the MAO-A subtype of inhibitors, making this drug safer to use.

By the 1960s, it was thought that the mode of action of tricyclics was to inhibit norepinephrine reuptake. However, norepinephrine reuptake became associated with stimulating effects. Later tricyclics were thought to affect serotonin as proposed in 1969 by Carlsson and Lindqvist as well as Lapin and Oxenkrug.

Second-generation antidepressants

Researchers began a process of rational drug design to isolate antihistamine-derived compounds that would selectively target these systems. The first such compound to be patented was zimelidine in 1971, while the first released clinically was indalpine. Fluoxetine was approved for commercial use by the US Food and Drug Administration (FDA) in 1988, becoming the first blockbuster SSRI. Fluoxetine was developed at Eli Lilly and Company in the early 1970s by Bryan Molloy, Klaus Schmiegel, David T. Wong, and others. SSRIs became known as "novel antidepressants" along with other newer drugs such as SNRIs and NRIs with various selective effects.

Rapid-acting antidepressants

Esketamine (brand name Spravato), the first rapid-acting antidepressant to be approved for clinical treatment of depression, was introduced for this indication in March 2019 in the United States.

Research

A 2016 randomized controlled trial evaluated the rapid antidepressant effects of the psychedelic Ayahuasca in treatment-resistant depression with a positive outcome. In 2018, the FDA granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatment-resistant depression and in 2019, the FDA granted Breakthrough Therapy Designation for psilocybin therapy treating major depressive disorder.

Publication bias and aged research

A 2018 systematic review published in The Lancet comparing the efficacy of 21 different first and second generation antidepressants found that antidepressant drugs tended to perform better and cause less adverse events when they were novel or experimental treatments compared to when they were evaluated again years later. Unpublished data was also associated with smaller positive effect sizes. However, the review did not find evidence of bias associated with industry funded research.

Society and culture

Prescription trends

United Kingdom

In the UK, figures reported in 2010 indicated that the number of antidepressants prescribed by the National Health Service (NHS) almost doubled over a decade. Further analysis published in 2014 showed that number of antidepressants dispensed annually in the community went up by 25 million in the 14 years between 1998 and 2012, rising from 15 million to 40 million. Nearly 50% of this rise occurred in the four years after the Great Recession, during which time the annual increase in prescriptions rose from 6.7% to 8.5%. These sources also suggest that aside from the recession, other factors that may influence changes in prescribing rates may include: improvements in diagnosis, a reduction of the stigma surrounding mental health, broader prescribing trends, GP characteristics, geographical location, and housing status. Another factor that may contribute to increasing consumption of antidepressants is the fact that these medications now are used for other conditions including social anxiety and post-traumatic stress disorder.

Between 2005 and 2017, the number of adolescents (12 to 17 years) in England who were prescribed antidepressants has doubled. On the other hand, antidepressant prescriptions for children aged 5–11 in England decreased between 1999 and 2017. From April 2015, prescriptions increased for both age groups (for people aged 0 to 17) and peaked during the first COVID lockdown in March 2020.

According to National Institute for Health and Care Excellence (NICE) guidelines, antidepressants for children and adolescents with depression and obsessive-compulsive disorder (OCD) should be prescribed together with therapy and after being assessed by a child and adolescent psychiatrist. However, between 2006 and 2017, only 1 in 4 of 12–17 year-olds who were prescribed an SSRI by their GP had seen a specialist psychiatrist and 1 in 6 has seen a pediatrician. Half of these prescriptions were for depression and 16% for anxiety, the latter not being licensed for treatment with antidepressants. Among the suggested possible reasons why GPs are not following the guidelines are the difficulties of accessing talking therapies, long waiting lists, and the urgency of treatment. According to some researchers, strict adherence to treatment guidelines would limit access to effective medication for young people with mental health problems.

United States

In the United States, antidepressants were the most commonly prescribed medication in 2013. Of the estimated 16 million "long term" (over 24 months) users, roughly 70 percent are female. As of 2017, about 16.5% of white people in the United States took antidepressants compared with 5.6% of black people in the United States.

United States: The most commonly prescribed antidepressants in the US retail market in 2010 were:

Netherlands: In the Netherlands, paroxetine is the most prescribed antidepressant, followed by amitriptyline, citalopram and venlafaxine.

Adherence

As of 2003, worldwide, 30% to 60% of people did not follow their practitioner's instructions about taking their antidepressants, and as of 2013 in the US, it appeared that around 50% of people did not take their antidepressants as directed by their practitioner.

When people fail to take their antidepressants, there is a greater risk that the drug will not help, that symptoms get worse, that they miss work or are less productive at work, and that the person may be hospitalized.

Social science perspective

Some academics have highlighted the need to examine the use of antidepressants and other medical treatments in cross-cultural terms, because various cultures prescribe and observe different manifestations, symptoms, meanings, and associations of depression and other medical conditions within their populations. These cross-cultural discrepancies, it has been argued, then have implications on the perceived efficacy and use of antidepressants and other strategies in the treatment of depression in these different cultures. In India, antidepressants are largely seen as tools to combat marginality, promising the individual the ability to reintegrate into society through their use—a view and association not observed in the West.

Environmental impacts

Because most antidepressants function by inhibiting the reuptake of neurotransmitters serotonin, dopamine, and norepinephrine these drugs can interfere with natural neurotransmitter levels in other organisms impacted by indirect exposure. Antidepressants fluoxetine and sertraline have been detected in aquatic organisms residing in effluent-dominated streams. The presence of antidepressants in surface waters and aquatic organisms has caused concern because ecotoxicological effects on aquatic organisms due to fluoxetine exposure have been demonstrated.

Coral reef fish have been demonstrated to modulate aggressive behavior through serotonin. Artificially increasing serotonin levels in crustaceans can temporarily reverse social status and turn subordinates into aggressive and territorial dominant males.

Exposure to Fluoxetine has been demonstrated to increase serotonergic activity in fish, subsequently reducing aggressive behavior. Perinatal exposure to Fluoxetine at relevant environmental concentrations has been shown to lead to significant modifications of memory processing in 1-month-old cuttlefish. This impairment may disadvantage cuttlefish and decrease their survival. Somewhat less than 10% of orally administered Fluoxetine is excreted from humans unchanged or as glucuronide.

See also

• Antidepressants in Japan
• Atypical antidepressant
• Depression and natural therapies
• Depression in childhood and adolescence
• List of investigational antidepressants
• Management of depression

References

1. ^ Jennings L (2018). "Antidepressants". In Grossberg GT, Kinsella LJ (eds.). Clinical Psychopharmacology for Neurologists. Springer. pp. 45–71. doi:10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9.
2. Ghaemi SN (2019). Clinical Psychopharmacology: Principles and Practice. New York: Oxford University Press. p. 90. ISBN 9780199995486.
3. Healy D, Le Noury J, Mangin D (May 2018). "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". The International Journal of Risk & Safety in Medicine. 29 (3–4): 125–134. doi:10.3233/JRS-180744. PMC 6004900. PMID 29733030.
4. Bahrick AS (2008). "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence". The Open Psychology Journal. 1: 42–50. doi:10.2174/1874350100801010042.
5. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K (May 2013). "Strategies for managing sexual dysfunction induced by antidepressant medication". The Cochrane Database of Systematic Reviews. 5 (5): CD003382. doi:10.1002/14651858.CD003382.pub3. PMID 23728643.
6. Kennedy SH, Rizvi S (April 2009). "Sexual dysfunction, depression, and the impact of antidepressants". Journal of Clinical Psychopharmacology. 29 (2): 157–164. doi:10.1097/jcp.0b013e31819c76e9. PMID 19512977. S2CID 739831.
7. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277), 11 June 20191, EMA/PRAC/265221/2019, Pharmacovigilance Risk Assessment Committee (PRAC)
8. Sansone RA, Sansone LA (October 2010). "SSRI-Induced Indifference". Psychiatry. 7 (10): 14–18. PMC 2989833. PMID 21103140.
9. "Is your antidepressant making life a little too blah?". Harvard Health Publishing. 8 November 2016. Retrieved 25 February 2021.
10. "Half of Patients on Antidepressants Experience Emotional Blunting". HCPLive. 19 June 2017. Retrieved 25 February 2021.
11. "Revisions to Product Labeling" (PDF). FDA. Archived (PDF) from the original on 9 October 2022. Retrieved 10 November 2018.
12. ^ Wilson E, Lader M (December 2015). "A review of the management of antidepressant discontinuation symptoms". Therapeutic Advances in Psychopharmacology. 5 (6): 357–368. doi:10.1177/2045125315612334. PMC 4722507. PMID 26834969.
13. ^ Gabriel M, Sharma V (May 2017). "Antidepressant discontinuation syndrome". CMAJ. 189 (21): E747. doi:10.1503/cmaj.160991. PMC 5449237. PMID 28554948.
14. ^ Barth M, Kriston L, Klostermann S, Barbui C, Cipriani A, Linde K (February 2016). "Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials". The British Journal of Psychiatry. 208 (2): 114–119. doi:10.1192/bjp.bp.114.150136. PMID 26834168.
15. ^ Jakobsen JC, Gluud C, Kirsch I (August 2020). "Should antidepressants be used for major depressive disorder?". BMJ Evidence-Based Medicine. 25 (4): 130. doi:10.1136/bmjebm-2019-111238. PMC 7418603. PMID 31554608.
16. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al. (August 2016). "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis". Lancet. 388 (10047): 881–890. doi:10.1016/S0140-6736(16)30385-3. hdl:11380/1279478. PMID 27289172. S2CID 19728203. When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. All antidepressants were more efficacious than a placebo in adults with major depressive disorder
17. Safer DJ, Zito JM (2019). "Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns". Frontiers in Psychiatry. 10: 705. doi:10.3389/fpsyt.2019.00705. PMC 6797591. PMID 31681028.
18. Hengartner MP (2020). "Editorial: Antidepressant Prescriptions in Children and Adolescents". Frontiers in Psychiatry. 11: 600283. doi:10.3389/fpsyt.2020.600283. PMC 7661954. PMID 33192742.
19. ^ "The most effective antidepressants for adults revealed in major review". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 3 April 2018. doi:10.3310/signal-00580.
20. ^ Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of twenty-one antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.
21. Kirsch I (January 2014). "Antidepressants and the Placebo Effect". Zeitschrift für Psychologie. 222 (3): 128–134. doi:10.1027/2151-2604/a000176. PMC 4172306. PMID 25279271.
22. Turner EH, Rosenthal R (March 2008). "Efficacy of antidepressants". The BMJ. 336 (7643): 516–517. doi:10.1136/bmj.39510.531597.80. PMC 2265347. PMID 18319297.
23. National Collaborating Centre for Mental Health (UK) (2010). Depression: The Treatment and Management of Depression in Adults. National Institute for Health and Clinical Excellence: Guidance (Updated ed.). British Psychological Society. ISBN 978-1-904671-85-5. PMID 22132433.
24. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration". PLOS Medicine. 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMC 2253608. PMID 18303940.
25. Whitaker R, Cosgrove L (23 April 2015). Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. Palgrave Macmillan US. ISBN 9781137506924.
26. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA (20 July 2022). "The serotonin theory of depression: a systematic umbrella review of the evidence". Molecular Psychiatry. 28 (8): 3243–3256. doi:10.1038/s41380-022-01661-0. ISSN 1359-4184. PMC 10618090. PMID 35854107. S2CID 250646781.
27. Ghaemi N (2022). Has the Serotonin Hypothesis Been Debunked?. Retrieved 2 May 2023.
28. Nutt DJ (30 April 2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". The Journal of Clinical Psychiatry. 69 (suppl E1): 4–7. PMID 18494537.
29. ^ "Depression in adults: treatment and management". National Institute for Health and Care Excellence. 29 June 2022.
30. Work Group on Major Depressive Disorder (October 2010). "Practice Guideline for the Treatment of Patients With Major Depressive Disorder" (PDF) (Third ed.). American Psychiatric Association. Archived (PDF) from the original on 9 October 2022.
31. Moncrieff J, Kirsch I (July 2015). "Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences". Contemporary Clinical Trials. 43: 60–62. doi:10.1016/j.cct.2015.05.005. PMID 25979317.
32. Kirsch I (2010). The Emperor's New Drugs: Exploding the Antidepressant Myth. Basic Books. pp. 80. ISBN 978-0-465-02016-4.
33. Antonuccio DO, Burns DD, Danton WG (2002). "Antidepressants: a triumph of marketing over science?". Prevention and Treatment. 5. doi:10.1037/1522-3736.5.1.525c.
34. Antonuccio DO, Danton WG, DeNelsky GY, Greenberg RP, Gordon JS (1999). "Raising questions about antidepressants". Psychotherapy and Psychosomatics. 68 (1): 3–14. doi:10.1159/000012304. PMID 9873236. S2CID 13524296.
35. "Prozac may be the best treatment for young people with depression – but more research is needed". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 12 October 2020. doi:10.3310/alert_41917. S2CID 242952585.
36. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. (July 2020). "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis". The Lancet. Psychiatry. 7 (7): 581–601. doi:10.1016/S2215-0366(20)30137-1. PMC 7303954. PMID 32563306.
37. ^ Boaden K, Tomlinson A, Cortese S, Cipriani A (2 September 2020). "Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment". Frontiers in Psychiatry. 11: 717. doi:10.3389/fpsyt.2020.00717. PMC 7493620. PMID 32982805.
38. ^ Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al. (Cochrane Common Mental Disorders Group) (May 2021). "New generation antidepressants for depression in children and adolescents: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2021 (5): CD013674. doi:10.1002/14651858.CD013674.pub2. PMC 8143444. PMID 34029378.
39. Wiesinger T, Kremer S, Bschor T, Baethge C (March 2023). "Antidepressants and Quality of Life in Patients with Major Depressive Disorder – Systematic Review and Meta-analysis of Double-blind, Placebo-controlled RCTs". Acta Psychiatr Scand. 147 (6): 545–560. doi:10.1111/acps.13541. PMID 36905396. S2CID 257438412.
40. Teng T, Zhang Z, Yin B, Guo T, Wang X, Hu J, et al. (May 2022). "Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis". Transl Psychiatry. 12 (1): 183. doi:10.1038/s41398-022-01951-9. PMC 9068747. PMID 35508443.
41. Paludan-Müller AS, Sharma T, Rasmussen K, Gøtzsche PC (May 2021). "Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants". Int J Risk Saf Med. 32 (2): 87–99. doi:10.3233/JRS-200051. PMID 33044196. S2CID 222299860.
42. ^ "Antidepressants for children and teenagers: what works for anxiety and depression?". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 3 November 2022. doi:10.3310/nihrevidence_53342. S2CID 253347210.
43. ^ Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, et al. (June 2021). "Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review". World Psychiatry. 20 (2): 244–275. doi:10.1002/wps.20881. PMC 8129843. PMID 34002501.
44. ^ Kirsch I (2019). "Placebo Effect in the Treatment of Depression and Anxiety". Front Psychiatry. 10: 407. doi:10.3389/fpsyt.2019.00407. PMC 6584108. PMID 31249537.
45. ^ Li F, Nasir M, Olten B, Bloch MH (October 2019). "Meta-Analysis of Placebo Response in Adult Antidepressant Trials". CNS Drugs. 33 (10): 971–980. doi:10.1007/s40263-019-00662-y. PMID 31573058. S2CID 203609845.
46. ^ National Collaborating Centre for Mental Health and the National Collaborating Centre for Primary Care (January 2011). "Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults" (PDF). NICE clinical guideline 113. Archived from the original (PDF) on 21 October 2012. Retrieved 20 February 2013.
47. Canton J, Scott KM, Glue P (May 2012). "Optimal treatment of social phobia: systematic review and meta-analysis". Neuropsychiatric Disease and Treatment. 8: 203–215. doi:10.2147/NDT.S23317. PMC 3363138. PMID 22665997.
48. Hansen RA, Gaynes BN, Gartlehner G, Moore CG, Tiwari R, Lohr KN (May 2008). "Efficacy and tolerability of second-generation antidepressants in social anxiety disorder". International Clinical Psychopharmacology. 23 (3): 170–179. doi:10.1097/YIC.0b013e3282f4224a. PMC 2657552. PMID 18408531.
49. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (January 2008). "Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)". The Cochrane Database of Systematic Reviews. 2008 (1): CD001765. doi:10.1002/14651858.CD001765.pub3. PMC 7025764. PMID 18253995.
50. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I (September 2012). "Evidence-based pharmacotherapy of obsessive-compulsive disorder". The International Journal of Neuropsychopharmacology. 15 (8): 1173–1191. doi:10.1017/S1461145711001829. hdl:2299/216. PMID 22226028.
51. "Paroxetine prescribing information" (PDF). Archived from the original (PDF) on 19 February 2015. Retrieved 30 January 2015.
52. "Sertraline prescribing information" (PDF). Archived (PDF) from the original on 16 June 2015. Retrieved 30 January 2015.
53. "Obsessive-compulsive disorder" (PDF). Clinical Guideline 31. The National Institute for Health and Care Excellence. November 2005. Archived from the original (PDF) on 6 December 2008.
54. Kellner M (June 2010). "Drug treatment of obsessive-compulsive disorder". Dialogues in Clinical Neuroscience. 12 (2): 187–197. doi:10.31887/DCNS.2010.12.2/mkellner. PMC 3181958. PMID 20623923.
55. Sugarman MA, Kirsch I, Huppert JD (August 2017). "Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis". J Affect Disord. 218: 217–226. doi:10.1016/j.jad.2017.04.068. PMID 28477500.
56. Alexander W (January 2012). "Pharmacotherapy for Post-traumatic Stress Disorder in Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents". P & T. 37 (1): 32–38. PMC 3278188. PMID 22346334.
57. Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, et al. (April 2018). "Antidepressants versus placebo for panic disorder in adults". The Cochrane Database of Systematic Reviews. 2018 (4): CD010676. doi:10.1002/14651858.CD010676.pub2. PMC 6494573. PMID 29620793.
58. Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, et al. (September 2016). "Antidepressants and benzodiazepines for panic disorder in adults". The Cochrane Database of Systematic Reviews. 2016 (9): CD011567. doi:10.1002/14651858.CD011567.pub2. PMC 6457579. PMID 27618521.
59. Andrisano C, Chiesa A, Serretti A (January 2013). "Newer antidepressants and panic disorder: a meta-analysis". International Clinical Psychopharmacology. 28 (1): 33–45. doi:10.1097/YIC.0b013e32835a5d2e. PMID 23111544. S2CID 24967691.
60. ^ "Eating disorders in over 8s: management" (PDF). Clinical guideline . United Kingdom: National Institute for Health Care Excellence (NICE). 28 January 2004. Archived (PDF) from the original on 27 March 2014.
61. "Bupropion: MedlinePlus Drug Information". Archived from the original on 8 May 2016. Retrieved 24 May 2016.
62. ^ "Practice guideline for the treatment of patients with eating disorders". National Guideline Clearinghouse. Agency for Healthcare Research and Quality. 5 July 2018. Archived from the original on 25 May 2013.
63. Flament MF, Bissada H, Spettigue W (March 2012). "Evidence-based pharmacotherapy of eating disorders". Int. J. Neuropsychopharmacol. 15 (2): 189–207. doi:10.1017/S1461145711000381. PMID 21414249.
64. Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C (April 2012). "The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis". CNS Drugs. 26 (4): 297–307. doi:10.2165/11598970-000000000-00000. PMID 22452526. S2CID 207301478.
65. Carville SF, Arendt-Nielsen L, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, et al. (April 2008). "EULAR evidence-based recommendations for the management of fibromyalgia syndrome". Annals of the Rheumatic Diseases. 67 (4): 536–541. doi:10.1136/ard.2007.071522. hdl:2434/664614. PMID 17644548. S2CID 12121672.
66. Lunn MP, Hughes RA, Wiffen PJ (January 2014). "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia". The Cochrane Database of Systematic Reviews. 1 (1): CD007115. doi:10.1002/14651858.CD007115.pub3. PMC 10711341. PMID 24385423.
67. ^ Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ (July 2015). "Amitriptyline for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 2015 (7): CD008242. doi:10.1002/14651858.CD008242.pub3. PMC 6447238. PMID 26146793.
68. Agabio R, Trogu E, Pani PP (April 2018). "Antidepressants for the treatment of people with co-occurring depression and alcohol dependence". The Cochrane Database of Systematic Reviews. 2018 (4): CD008581. doi:10.1002/14651858.CD008581.pub2. PMC 6494437. PMID 29688573.
69. "Narcolepsy Information Page". National Institute of Neurological Disorders and Stroke. 27 March 2019. Retrieved 11 April 2020.
70. Richards BL, Whittle SL, Buchbinder R (November 2011). "Antidepressants for pain management in rheumatoid arthritis". The Cochrane Database of Systematic Reviews (11): CD008920. doi:10.1002/14651858.CD008920.pub2. PMID 22071859.
71. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M (March 2010). "Antidepressants for depression in physically ill people". The Cochrane Database of Systematic Reviews (3): CD007503. doi:10.1002/14651858.CD007503.pub2. PMID 20238354.
72. Prado CE, Watt S, Crowe SF (March 2018). "A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples". Neuropsychology Review. 28 (1): 32–72. doi:10.1007/s11065-018-9369-5. PMID 29446012.
73. Halman A, Kong G, Sarris J, Perkins D (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol. 38 (1): 3–18. doi:10.1177/02698811231211219. PMC 10851641. PMID 37982394.
74. Yates G, Melon E (January 2024). "Trip-killers: a concerning practice associated with psychedelic drug use". Emerg Med J. 41 (2): 112–113. doi:10.1136/emermed-2023-213377. PMID 38123961.
75. Suran M (February 2024). "Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs". JAMA. 331 (8): 632–634. doi:10.1001/jama.2023.28257. PMID 38294772.
76. Baghai TC, Möller HJ, Rupprecht R (2006). "Recent progress in pharmacological and non-pharmacological treatment options of major depression". Current Pharmaceutical Design. 12 (4): 503–515. doi:10.2174/138161206775474422. PMID 16472142.
77. ^ Ruhé HG, Huyser J, Swinkels JA, Schene AH (December 2006). "Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review" (PDF). The Journal of Clinical Psychiatry. 67 (12): 1836–1855. doi:10.4088/JCP.v67n1203. PMID 17194261. S2CID 9758110. Archived from the original (PDF) on 16 February 2019.
78. Tranter R, O'Donovan C, Chandarana P, Kennedy S (July 2002). "Prevalence and outcome of partial remission in depression". Journal of Psychiatry & Neuroscience. 27 (4): 241–247. PMC 161658. PMID 12174733.
79. Byrne SE, Rothschild AJ (June 1998). "Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments". The Journal of Clinical Psychiatry. 59 (6): 279–288. doi:10.4088/JCP.v59n0602. PMID 9671339.
80. "Antidepressant Use in Persons Aged 12 and Over: United States, 2005–2008". cdc.gov. Products – Data Briefs – Number 76 – October 2011. Centers for Disease Control and Prevention. Archived from the original on 4 February 2016. Retrieved 4 February 2016.
81. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M (June 2000). "Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians". Canadian Journal of Psychiatry. 45 (5): 476–481. doi:10.1177/070674370004500509. PMID 10900529. S2CID 12904378.
82. Wilson C (2 October 2018). "Nobody can agree about antidepressants. Here's what you need to know". New Scientist. New Scientist Ltd. Retrieved 23 January 2023.
83. ^ Warren JB (2020). "The trouble with antidepressants: why the evidence overplays evidence and underplays risks—an essay by John B Warren". The BMJ. 370: m3200. doi:10.1136/bmj.m3200. PMID 32883743. S2CID 221468976.
84. ^ Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I (August 2022). "Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis". The BMJ. 378: e067606. doi:10.1136/bmj-2021-067606. PMC 9344377. PMID 35918097.
85. ^ Hengartner MP, Plöderl M (2018). "Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter!". Front Psychiatry. 9: 517. doi:10.3389/fpsyt.2018.00517. PMC 6199395. PMID 30386270.
86. McCormack J, Korownyk C (2018). "Effectiveness of antidepressants". The BMJ. 360: k1073. doi:10.1136/bmj.k1073. PMID 29523598. S2CID 3925654.
87. ^ Jakobsen JC, Gluud C, Kirsch I (August 2020). "Should antidepressants be used for major depressive disorder?". BMJ Evid Based Med. 25 (4): 130. doi:10.1136/bmjebm-2019-111238. PMC 7418603. PMID 31554608.
88. ^ Moncrieff J, Kirsch I (July 2015). "Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences". Contemp Clin Trials. 43: 60–2. doi:10.1016/j.cct.2015.05.005. PMID 25979317.
89. Pariante CM (2022). "Depression is both psychosocial and biological; antidepressants are both effective and in need of improvement; psychiatrists are both caring human beings and doctors who prescribe medications. Can we all agree on this? a commentary on 'Read & Moncrieff – depression: why drugs and electricity are not the answer'". Psychological Medicine. 52 (8): 1411–1413. doi:10.1017/S0033291722000770. PMID 35362404.
90. ^ Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020). "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS One. 15 (2): e0229381. Bibcode:2020PLoSO..1529381H. doi:10.1371/journal.pone.0229381. PMC 7043778. PMID 32101579.
91. Luedtke A, Kessler RC (2021). "New Directions in Research on Heterogeneity of Treatment Effects for Major Depression". JAMA Psychiatry. 78 (5): 478–480. doi:10.1001/jamapsychiatry.2020.4489. PMID 33595616. S2CID 231944660.
92. Khan A, Brown WA (2015). "Antidepressants versus placebo in major depression: an overview". World Psychiatry. 14 (3): 294–300. doi:10.1002/wps.20241. PMC 4592645. PMID 26407778.
93. ^ Nutt DJ, Malizia AL (2008). "Why does the world have such a 'down' on antidepressants?". Journal of Psychopharmacology. 22 (3): 223–226. doi:10.1177/0269881108091877. PMID 18541622. S2CID 45965987.
94. Boesen K, Gøtzsche PC, Ioannidis JP (2021). "EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations". Epidemiology and Psychiatric Sciences. 30: e35. doi:10.1017/S2045796021000147. PMC 8157504. PMID 33926608.
95. ^ Read J, Moncrieff J (2022). "Depression: why drugs and electricity are not the answer" (PDF). Psychological Medicine. 52 (8): 1401–1410. doi:10.1017/S0033291721005031. PMID 35100527. S2CID 246442707.
96. Giraldi T (2017). Unhappiness, sadness and 'depression'. London, UK: Palgrave Macmillan. pp. 108–110. ISBN 978-3-319-57657-2.
97. ^ Munkholm K, Paludan-Müller AS, Boesen K (June 2019). "Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis". BMJ Open. 9 (6): e024886. doi:10.1136/bmjopen-2018-024886. PMC 6597641. PMID 31248914.
98. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). "Selective publication of antidepressant trials and its influence on apparent efficacy". The New England Journal of Medicine. 358 (3): 252–260. doi:10.1056/NEJMsa065779. PMID 18199864.
99. Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA (2022). "Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials". PLOS Medicine. 19 (1): e1003886. doi:10.1371/journal.pmed.1003886. PMC 8769343. PMID 35045113.
100. Hughes S, Cohen D, Jaggi R (2014). "Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study". BMJ Open. 4 (7): e005535. doi:10.1136/bmjopen-2014-005535. PMC 4091397. PMID 25009136.
101. ^ Hengartner MP (2022). Evidence-biased Antidepressant Prescription. Springer International Publishing. doi:10.1007/978-3-030-82587-4. ISBN 978-3-030-82586-7. S2CID 245017942.
102. ^ Kirsch I (2014). "The Emperor's New Drugs: Medication and Placebo in the Treatment of Depression". Placebo. Handbook of Experimental Pharmacology. Vol. 225. Springer Berlin Heidelberg. pp. 291–303. doi:10.1007/978-3-662-44519-8_16. eISSN 1865-0325. ISBN 978-3-662-44518-1. ISSN 0171-2004. PMID 25304538.
103. Sharma T, Guski LS, Freund N, Gøtzsche PC (2016). "Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports". The BMJ. 352: i65. doi:10.1136/bmj.i65. PMC 4729837. PMID 26819231.
104. Bielefeldt AØ, Danborg PB, Gøtzsche PC (2016). "Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers". Journal of the Royal Society of Medicine. 109 (10): 381–392. doi:10.1177/0141076816666805. PMC 5066537. PMID 27729596.
105. Fava GA (2014). "Rational use of antidepressant drugs". Psychotherapy and Psychosomatics. 83 (4): 197–204. doi:10.1159/000362803. PMID 24969962. S2CID 32506580.
106. ^ Lacasse JR, Leo J (December 2005). "Serotonin and depression: a disconnect between the advertisements and the scientific literature". PLOS Med. 2 (12): e392. doi:10.1371/journal.pmed.0020392. PMC 1277931. PMID 16268734.
107. ^ Lacasse JR, Leo J (October 2015). "Antidepressants and the Chemical Imbalance Theory of Depression: A Reflection and Update on the Discourse". The Behavior Therapist. 38 (7): 206–213.
108. ^ Lacasse JR (September 2005). "Consumer Advertising of Psychiatric Medications Biases the Public Against Nonpharmacological Treatment". Ethical Human Psychology and Psychiatry. 7 (3): 175–179. doi:10.1891/1559-4343.7.3.175. eISSN 1938-9000. ISSN 1559-4343. PMID 16604742. S2CID 14133908.
109. ^ Ang B, Horowitz M, Moncrieff J (December 2022). "Is the chemical imbalance an 'urban legend'? An exploration of the status of the serotonin theory of depression in the scientific literature". SSM – Mental Health. 2: 100098. doi:10.1016/j.ssmmh.2022.100098. ISSN 2666-5603. S2CID 248246338.
110. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. (2016). "Major depressive disorder". Nature Reviews Disease Primers. 2: 16065. doi:10.1038/nrdp.2016.65. PMID 27629598. S2CID 4047310.
111. Kendrick T, Pilling S, Mavranezouli I, Megnin-Viggars O, Ruane C, Eadon H, et al. (2022). "Management of depression in adults: summary of updated NICE guidance". The BMJ. 378: o1557. doi:10.1136/bmj.o1557. PMID 35858703. S2CID 250644758.
112. Bschor T, Baethge C (2010). "No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy". Acta Psychiatrica Scandinavica. 121 (3): 174–9. doi:10.1111/j.1600-0447.2009.01458.x. PMID 19703121. S2CID 8341512.
113. DeBattista C, Lembke A (2005). "Update on augmentation of antidepressant response in resistant depression". Current Psychiatry Reports. 7 (6): 435–40. doi:10.1007/s11920-005-0064-x. PMID 16318821. S2CID 25499899.
114. Lam RW, Wan DD, Cohen NL, Kennedy SH (2002). "Combining Antidepressants for Treatment-Resistant Depression". The Journal of Clinical Psychiatry. 63 (8): 685–93. doi:10.4088/JCP.v63n0805. PMID 12197448.
115. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013). "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials" (PDF). The Journal of Clinical Psychiatry. 74 (11): 1101–7. doi:10.4088/JCP.13r08560. PMID 24330897. S2CID 13911763. Archived from the original (PDF) on 15 February 2020.
116. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. (2003). "Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review". The Lancet. 361 (9358): 653–61. doi:10.1016/S0140-6736(03)12599-8. PMID 12606176. S2CID 20198748.
117. Targum SD (March 2014). "Identification and treatment of antidepressant tachyphylaxis". Innovations in Clinical Neuroscience. 11 (3–4): 24–28. PMC 4008298. PMID 24800130.
118. Fava GA, Offidani E (August 2011). "The mechanisms of tolerance in antidepressant action". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35 (7): 1593–1602. doi:10.1016/j.pnpbp.2010.07.026. PMID 20728491. S2CID 207409469.
119. Fava GA, Park SK, Sonino N (November 2006). "Treatment of recurrent depression". Expert Review of Neurotherapeutics. 6 (11): 1735–1740. doi:10.1586/14737175.6.11.1735. PMID 17144786. S2CID 22808803.
120. Petersen TJ (May 2006). "Enhancing the efficacy of antidepressants with psychotherapy". Journal of Psychopharmacology. 20 (3 Suppl): 19–28. doi:10.1177/1359786806064314. PMID 16644768. S2CID 23649861.
121. "Voorkom Depressie – Preventieve Cognitieve Therapie". voorkomdepressie.nl.
122. Breedvelt JJ, Warren FC, Segal Z, Kuyken W, Bockting CL (August 2021). "Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis". JAMA Psychiatry. 78 (8): 868–875. doi:10.1001/jamapsychiatry.2021.0823. PMC 8135055. PMID 34009273.
123. Allen A. "Coping With Side Effects of Depression Treatment". WebMD. Retrieved 4 February 2019.
124. Birmes P, Coppin D, Schmitt L, Lauque D (May 2003). "Serotonin syndrome: a brief review". CMAJ. 168 (11): 1439–1442. PMC 155963. PMID 12771076.
125. Boyer EW, Shannon M (March 2005). "The serotonin syndrome" (PDF). The New England Journal of Medicine. 352 (11): 1112–1120. doi:10.1056/NEJMra041867. PMID 15784664. Archived from the original (PDF) on 18 June 2013.
126. Mason PJ, Morris VA, Balcezak TJ (July 2000). "Serotonin syndrome. Presentation of 2 cases and review of the literature". Medicine. 79 (4): 201–209. doi:10.1097/00005792-200007000-00001. PMID 10941349. S2CID 41036864.
127. Sampson E, Warner JP (November 1999). "Serotonin syndrome: potentially fatal but difficult to recognize". The British Journal of General Practice. 49 (448): 867–868. PMC 1313553. PMID 10818648.
128. Salvi V, Grua I, Cerveri G, Mencacci C, Barone-Adesi F (31 July 2017). "The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis". PLOS One. 12 (7): e0182088. Bibcode:2017PLoSO..1282088S. doi:10.1371/journal.pone.0182088. PMC 5536271. PMID 28759599. In our meta-analysis we found an association between exposure to ADs and new-onset diabetes, with a relative risk of 1.27. When we restricted the analysis to the studies to high NOS score the association between ADs and diabetes was even stronger. The results are in line with those from two previous meta-analyses that reported a 1.5-fold increase of diabetes among AD users.
129. Sathyanarayana Rao TS, Yeragani VK (2009). "Hypertensive crisis and cheese". Indian J Psychiatry. 51 (1): 65–6. doi:10.4103/0019-5545.44910. PMC 2738414. PMID 19742203.
130. Paykel ES (1995). "Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression". Acta Psychiatrica Scandinavica. Supplementum. 386: 22–27. doi:10.1111/j.1600-0447.1995.tb05920.x. PMID 7717091. S2CID 20488192.
131. Rochester MP, Kane AM, Linnebur SA, Fixen DR (June 2018). "Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence". Therapeutic Advances in Drug Safety. 9 (6): 297–308. doi:10.1177/2042098618772979. PMC 5971403. PMID 29854391.
132. Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM (July 2010). "Causes and management of drug-induced long QT syndrome". Proceedings. 23 (3): 250–255. doi:10.1080/08998280.2010.11928628. PMC 2900977. PMID 20671821.
133. Wang GH, Li P, Wang Y, Guo J, Wilson DL, Lo-Ciganic WH (October 2023). "Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis". J Clin Med. 12 (19): 6342. doi:10.3390/jcm12196342. PMC 10573169. PMID 37834986.
134. Pillinger T, Howes OD, Correll CU, Leucht S, Huhn M, Schneider-Thoma J, et al. (November 2023). "Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development". The Lancet. Psychiatry. 10 (11): 860–876. doi:10.1016/s2215-0366(23)00262-6. PMC 10878984. PMID 37774723.
135. "How to choose the right antidepressant or antipsychotic". NIHR Evidence. 5 September 2024.
136. Malm H (December 2012). "Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome". Ther Drug Monit. 34 (6): 607–14. doi:10.1097/FTD.0b013e31826d07ea. PMID 23042258. S2CID 22875385.
137. Rahimi R, Nikfar S, Abdollahi M (2006). "Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials". Reproductive Toxicology. 22 (4): 571–575. doi:10.1016/j.reprotox.2006.03.019. PMID 16720091.
138. ^ Nikfar S, Rahimi R, Hendoiee N, Abdollahi M (2012). "Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis". DARU Journal of Pharmaceutical Sciences. 20 (1): 75. doi:10.1186/2008-2231-20-75. PMC 3556001. PMID 23351929.
139. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W (2014). "A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight". General Hospital Psychiatry. 36 (1): 13–8. doi:10.1016/j.genhosppsych.2013.08.002. PMC 3877723. PMID 24094568.
140. Einarson TR, Kennedy D, Einarson A (2012). "Do findings differ across research design? The case of antidepressant use in pregnancy and malformations". J Popul Ther Clin Pharmacol. 19 (2): e334–48. PMID 22946124.
141. Riggin L, Frankel Z, Moretti M, Pupco A, Koren G (April 2013). "The fetal safety of fluoxetine: a systematic review and meta-analysis". J Obstet Gynaecol Can. 35 (4): 362–9. doi:10.1016/S1701-2163(15)30965-8. PMID 23660045.
142. Koren G, Nordeng HM (February 2013). "Selective serotonin reuptake inhibitors and malformations: case closed?". Semin Fetal Neonatal Med. 18 (1): 19–22. doi:10.1016/j.siny.2012.10.004. PMID 23228547.
143. "FDA Advising of Risk of Birth Defects with Paxil" (Press release). U.S. Food and Drug Administration. Archived from the original on 3 December 2013. Retrieved 29 November 2012.
144. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, et al. (April 2013). "Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis". JAMA Psychiatry. 70 (4): 436–443. doi:10.1001/jamapsychiatry.2013.684. PMID 23446732. S2CID 2065578.
145. Lanza di Scalea T, Wisner KL (2009). "Antidepressant Medication Use During Breastfeeding". Clinical Obstetrics and Gynecology. 52 (3): 483–97. doi:10.1097/GRF.0b013e3181b52bd6. PMC 2902256. PMID 19661763.
146. Sivagnanam G (2012). "Antidepressants". Journal of Pharmacology and Pharmacotherapeutics. 3 (3): 287–288. doi:10.1177/0976500X20120302. S2CID 248110770. ProQuest 1033762996. Archived from the original on 1 July 2018. Retrieved 21 March 2013.
147. Goldberg JF, Truman CJ (2003). "Antidepressant-induced mania: An overview of current controversies". Bipolar Disorders. 5 (6): 407–20. doi:10.1046/j.1399-5618.2003.00067.x. PMID 14636364.
148. Benazzi F (1997). "Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice". J Affect Disord. 46 (1): 73–7. doi:10.1016/S0165-0327(97)00082-7. PMID 9387089.
149. Barbuti M, Menculini G, Verdolini N, Pacchiarotti I, Kotzalidis GD, Tortorella A, et al. (April 2023). "A systematic review of manic/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs". Eur Neuropsychopharmacol. 73: 1–15. doi:10.1016/j.euroneuro.2023.04.013. hdl:2445/210406. PMID 37119556. S2CID 258334982.
150. ^ Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. (2009). "Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration". The BMJ. 339: b2880. doi:10.1136/bmj.b2880. PMC 2725270. PMID 19671933.
151. Friedman RA, Leon AC (2007). "Expanding the black box – depression, antidepressants, and the risk of suicide". N. Engl. J. Med. 356 (23): 2343–6. doi:10.1056/NEJMp078015. PMID 17485726.
152. "Antidepressant Use in Children, Adolescents, and Adults". Food and Drug Administration. Archived from the original on 19 December 2016.
153. "FDA Medication Guide for Antidepressants". Food and Drug Administration. Archived from the original on 18 August 2014. Retrieved 5 June 2014.
154. "Depression in adults: recognition and management" (PDF). Clinical guideline . The National Institute for Health and Care Excellence (NICE). 28 October 2009. Archived (PDF) from the original on 18 October 2012.
155. Healy D, Whitaker C (2003). "Antidepressants and suicide: risk-benefit conundrums". Journal of Psychiatry and Neuroscience. 28 (5): 331–337. PMC 193979. PMID 14517576.
156. Healy D, Aldred G (2005). "Antidepressant drug use and the risk of suicide" (PDF). International Review of Psychiatry. 17 (3): 163–172. doi:10.1080/09540260500071624. PMID 16194787. S2CID 6599566. Archived from the original (PDF) on 21 October 2013.
157. Grant JE, Potenza MN, eds. (2012). The Oxford handbook of impulse control disorders. Oxford: Oxford University Press. ISBN 978-0-19-538971-5.
158. Csoka AB, Csoka A, Bahrick A, Mehtonen OP (January 2008). "Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors". The Journal of Sexual Medicine. 5 (1): 227–233. doi:10.1111/j.1743-6109.2007.00630.x. PMID 18173768. S2CID 15471717.
159. Healy D, Le Noury J, Mangin D (4 June 2018). "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". The International Journal of Risk & Safety in Medicine. 29 (3–4): 125–134. doi:10.3233/JRS-180744. PMC 6004900. PMID 29733030.
160. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". The Journal of Clinical Psychiatry. 62 (Suppl 3): 10–21. PMID 11229449.
161. Serretti A, Chiesa A (June 2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology. 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. S2CID 1663570.
162. Chebili S, Abaoub A, Mezouane B, Le Goff JF (1998). "". L'Encephale (in French). 24 (3): 180–184. PMID 9696909.
163. Keltner NL, McAfee KM, Taylor CL (2009). "Biological Perspectives". Perspectives in Psychiatric Care. 38 (3): 111–6. doi:10.1111/j.1744-6163.2002.tb00665.x. PMID 12385082.
164. Ozmenler NK, Karlidere T, Bozkurt A, Yetkin S, Doruk A, Sutcigil L, et al. (2008). "Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors". Hum Psychopharmacol. 23 (4): 321–6. doi:10.1002/hup.929. PMID 18278806. S2CID 39616771.
165. Schwasinger-Schmidt TE, Macaluso M (8 September 2018). "Other Antidepressants". Antidepressants. Handbook of Experimental Pharmacology. Vol. 250. pp. 325–355. doi:10.1007/164_2018_167. ISBN 978-3-030-10948-6. PMID 30194544.
166. Marazziti D, Mucci F, Tripodi B, Carbone MG, Muscarella A, Falaschi V, et al. (April 2019). "Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs". Clin Neuropsychiatry. 16 (2): 75–85. PMC 8650205. PMID 34908941.
167. ^ Ma H, Cai M, Wang H (2021). "Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research". Front Psychiatry. 12: 792960. doi:10.3389/fpsyt.2021.792960. PMC 8712545. PMID 34970173.
168. Barnhart WJ, Makela EH, Latocha MJ (May 2004). "SSRI-induced apathy syndrome: a clinical review". J Psychiatr Pract. 10 (3): 196–9. doi:10.1097/00131746-200405000-00010. PMID 15330228. S2CID 26935586.
169. Sansone RA, Sansone LA (October 2010). "SSRI-Induced Indifference". Psychiatry (Edgmont). 7 (10): 14–8. PMC 2989833. PMID 21103140.
170. Price J, Cole V, Goodwin GM (September 2009). "Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study". Br J Psychiatry. 195 (3): 211–7. doi:10.1192/bjp.bp.108.051110. PMID 19721109.
171. Goodwin GM, Price J, De Bodinat C, Laredo J (October 2017). "Emotional blunting with antidepressant treatments: A survey among depressed patients". J Affect Disord. 221: 31–35. doi:10.1016/j.jad.2017.05.048. PMID 28628765. S2CID 3755520.
172. Read J, Williams J (2018). "Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects" (PDF). Curr Drug Saf. 13 (3): 176–186. doi:10.2174/1574886313666180605095130. PMID 29866014. S2CID 46934452.
173. ^ Camino S, Strejilevich SA, Godoy A, Smith J, Szmulewicz A (March 2022). "Are all antidepressants the same? The consumer has a point". Psychol Med. 53 (9): 4004–4011. doi:10.1017/S0033291722000678. PMID 35346413. S2CID 247777403.
174. Garland EJ, Baerg EA (2001). "Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents". J Child Adolesc Psychopharmacol. 11 (2): 181–6. doi:10.1089/104454601750284090. PMID 11436958.
175. Moncrieff J (October 2015). "Antidepressants: misnamed and misrepresented". World Psychiatry. 14 (3): 302–3. doi:10.1002/wps.20243. PMC 4592647. PMID 26407780.
176. Corruble E, de Bodinat C, Belaïdi C, Goodwin GM (November 2013). "Efficacy of Aomelatine and Escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial". Int J Neuropsychopharmacol. 16 (10): 2219–34. doi:10.1017/S1461145713000679. PMID 23823799.
177. Fagiolini A, Florea I, Loft H, Christensen MC (March 2021). "Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment". J Affect Disord. 283: 472–479. doi:10.1016/j.jad.2020.11.106. hdl:11365/1137950. PMID 33516560. S2CID 228877905.
178. Stimmel GL, Dopheide JA, Stahl SM (1997). "Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects". Pharmacotherapy. 17 (1): 10–21. doi:10.1002/j.1875-9114.1997.tb03674.x. PMID 9017762. S2CID 2454536. Archived from the original on 25 May 2021. Retrieved 17 January 2020.
179. "mirtazapine (Rx) – Remeron, Remeron SolTab". Medscape. WebMD. Archived from the original on 29 October 2013. Retrieved 19 November 2013.
180. Papakostas GI (2008). "Tolerability of modern antidepressants". J Clin Psychiatry. 69 (Suppl E1): 8–13. PMID 18494538.
181. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. (April 2005). "Meta-analysis: pharmacologic treatment of obesity". Ann. Intern. Med. 142 (7): 532–46. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465. S2CID 6964051.
182. "Effexor Medicines Data Sheet". Wyeth Pharmaceuticals Inc. 2006. Archived from the original on 17 September 2006. Retrieved 17 September 2006.
183. Kang S, Han M, Park CI, Jung I, Kim EH, Boo YJ, et al. (June 2021). "Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study". Scientific Reports. 11 (1): 13461. Bibcode:2021NatSR..1113461K. doi:10.1038/s41598-021-92821-9. PMC 8241982. PMID 34188108.
184. Rizzoli R, Cooper C, Reginster JY, Abrahamsen B, Adachi JD, Brandi ML, et al. (September 2012). "Antidepressant medications and osteoporosis". Bone. 51 (3): 606–613. doi:10.1016/j.bone.2012.05.018. PMID 22659406.
185. Zhou C, Fang L, Chen Y, Zhong J, Wang H, Xie P (June 2018). "Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis". Osteoporosis International. 29 (6): 1243–1251. doi:10.1007/s00198-018-4413-0. PMID 29435621. S2CID 23313396.
186. ^ Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, et al. (2017). "The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis". Psychother Psychosom. 86 (5): 268–282. doi:10.1159/000477940. PMID 28903117. S2CID 4830115.
187. ^ Warner CH, Bobo W, Warner C, Reid S, Rachal J (August 2006). "Antidepressant discontinuation syndrome". American Family Physician. 74 (3): 449–456. PMID 16913164.
188. ^ Davies J, Read J (October 2019). "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?". Addictive Behaviors. 97: 111–121. doi:10.1016/j.addbeh.2018.08.027. PMID 30292574.
189. ^ Fasipe O (2018). "Neuropharmacological classification of antidepressant agents based on their mechanisms of action". Archives of Medicine and Health Sciences. 6 (1): 81. doi:10.4103/amhs.amhs_7_18. ISSN 2321-4848. S2CID 81878024.
190. ^ Naguy A, Alamiri B (June 2022). "Antidepressants-A Misnomer? Clinical Impressionism or Scientific Empiricism?". Prim Care Companion CNS Disord. 24 (3). doi:10.4088/PCC.21br03084. PMID 35714379. S2CID 249652271.
191. ^ Stahl SM (19 November 2020). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. ISBN 978-1-108-92602-7.
192. Boland RJ, Keller MB (8 August 2008). "Antidepressants". Psychiatry. John Wiley & Sons, Ltd. pp. 2123–2160. doi:10.1002/9780470515167.ch101. ISBN 9780470515167.
193. Park SC, Shen WW (2023). "Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)". Tasman's Psychiatry. Cham: Springer International Publishing. pp. 1–53. doi:10.1007/978-3-030-42825-9_133-1. ISBN 978-3-030-42825-9.
194. Saxena PP, Bodkin JA (January 2019). "Opioidergic Agents as Antidepressants: Rationale and Promise". CNS Drugs. 33 (1): 9–16. doi:10.1007/s40263-018-0584-7. PMID 30430396.
195. Nishio Y, Lindsley CW, Bender AM (October 2024). "Classics in Chemical Neuroscience: Tianeptine". ACS Chem Neurosci. doi:10.1021/acschemneuro.4c00519. PMC 11587517. PMID 39382192.
196. ^ Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929-1950". J Hist Med Allied Sci. 61 (3): 288–323. doi:10.1093/jhmas/jrj039. PMID 16492800.
197. Ciccarone D (March 2011). "Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy". Prim Care. 38 (1): 41–58. doi:10.1016/j.pop.2010.11.004. PMC 3056348. PMID 21356420. In 1919, Japanese chemist Akira Ogata, as part of his effort to prove the structure of ephedrine, reported the synthesis of the closely related compound we now call methamphetamine, and this result was described in the Western literature (Amatsu & Kubota, 1913; Lee, 2011; Ogata, 1920). As a result, when competitors began to consider emulating SKF's success in the late 1930s, they turned to methamphetamine, which had nearly indistinguishable effects but—because its synthesis together with its pharmacological characteristics was published before 1920—was free from patent encumbrance. In any event, by 1940 Benzedrine Sulfate had achieved medical acclaim and quickly growing sales as an antidepressant effective for milder forms of the condition, both in the United States and the United Kingdom. In Germany, the Temmler drug firm quickly copied SKF, marketing methamphetamine (again, unprotected by patents) tablets under the Pervitin brand, with claims that it restored "joy in work" in cases of mild depression around 1938 (Rasmussen, 2006; Steinkamp, 2006).
198. Rasmussen N (2015). "Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses". Int Rev Neurobiol. 120: 9–25. doi:10.1016/bs.irn.2015.02.001. PMID 26070751.
199. Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". J Psychopharmacol. 27 (6): 479–496. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
200. ^ Brunton LL, Chabner B, Knollmann BC, eds. (2011). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
201. ^ Baumeister AA, Hawkins MF, Uzelac SM (June 2003). "The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis". J Hist Neurosci. 12 (2): 207–20. doi:10.1076/jhin.12.2.207.15535. PMID 12953623. S2CID 42407412.
202. ^ Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA (July 2022). "The serotonin theory of depression: a systematic umbrella review of the evidence". Mol Psychiatry. 28 (8): 3243–3256. doi:10.1038/s41380-022-01661-0. PMC 10618090. PMID 35854107. S2CID 250646781.
203. ^ Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. (March 2009). "The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression". Metabolic Brain Disease. 24 (1): 27–53. doi:10.1007/s11011-008-9118-1. hdl:11577/2380064. PMID 19085093. S2CID 4564675.
204. ^ Sanacora G, Treccani G, Popoli M (January 2012). "Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders". Neuropharmacology. 62 (1): 63–77. doi:10.1016/j.neuropharm.2011.07.036. PMC 3205453. PMID 21827775.
205. Menke A, Klengel T, Binder EB (2012). "Epigenetics, depression and antidepressant treatment". Current Pharmaceutical Design. 18 (36): 5879–5889. doi:10.2174/138161212803523590. PMID 22681167.
206. Vialou V, Feng J, Robison AJ, Nestler EJ (January 2013). "Epigenetic mechanisms of depression and antidepressant action". Annual Review of Pharmacology and Toxicology. 53 (1): 59–87. doi:10.1146/annurev-pharmtox-010611-134540. PMC 3711377. PMID 23020296.
207. Knudsen GM, Bloomfield M, Nutt D, Cowen P, de Picker L, Young A, et al. "Expert reaction to a review paper on the 'Serotonin Theory of Depression'". Science Media Centre. Retrieved 28 August 2022.
208. ^ Moncrieff J, Horowitz M (28 July 2022). "Response to Criticism of Our Serotonin Paper". Mad in America. Retrieved 28 August 2022.
209. ^ Strawbridge R, Javed RR, Cave J, Jauhar S, Young AH (August 2022). "The effects of reserpine on depression: A systematic review". J Psychopharmacol. 37 (3): 248–260. doi:10.1177/02698811221115762. PMC 10076328. PMID 36000248. S2CID 251765916.
210. Leo J, Lacasse JR (28 November 2007). "The Media and the Chemical Imbalance Theory of Depression". Society. 45 (1): 35–45. doi:10.1007/s12115-007-9047-3. eISSN 1936-4725. ISSN 0147-2011. S2CID 2176245.
211. Kirsch I (26 January 2010). The Emperor's New Drugs: Exploding the Antidepressant Myth. Basic Books. ISBN 978-0-465-02104-8. OCLC 1037471689.
212. Read J, Moncrieff J (June 2022). "Depression: why drugs and electricity are not the answer" (PDF). Psychol Med. 52 (8): 1401–1410. doi:10.1017/S0033291721005031. PMID 35100527. S2CID 246442707.
213. Hengartner MP, Plöderl M (July 2018). "False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs". Ethical Human Psychology and Psychiatry. 20 (1): 6–16. doi:10.1891/1559-4343.20.1.6. eISSN 1938-9000. ISSN 1559-4343. S2CID 149608377.
214. ^ Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.
215. Chen EG, Oliver AK, Raz A (January 2023). "Irving Kirsch opens a window on antidepressant medications". Am J Clin Hypn. 65 (3): 223–240. doi:10.1080/00029157.2022.2121678. PMID 36638223. S2CID 255775806.
216. Hengartner MP, Plöderl M (April 2022). "Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression". BMJ Evid Based Med. 27 (2): 69–73. doi:10.1136/bmjebm-2020-111600. PMID 33593736. S2CID 231939760.
217. Huneke NT, Aslan IH, Fagan H, Phillips N, Tanna R, Cortese S, et al. (June 2022). "Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review". Int J Neuropsychopharmacol. 25 (6): 433–447. doi:10.1093/ijnp/pyac009. PMC 9211006. PMID 35078210.
218. Brietzke C, Cesario JC, Hettinga FJ, Pires FO (August 2022). "The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance" (PDF). Eur J Appl Physiol. 122 (11): 2321–2329. doi:10.1007/s00421-022-05029-8. PMID 36006479. S2CID 251809051.
219. Fricchione G, Stefano GB (May 2005). "Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries". Med Sci Monit. 11 (5): MS54–65. PMID 15874901.
220. ^ Hengartner MP (April 2020). "Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission". BMJ Evid Based Med. 25 (2): 46–48. doi:10.1136/bmjebm-2019-111161. PMID 30975717. S2CID 109941636.
221. Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA (2012). "A systematic review of comparative efficacy of treatments and controls for depression". PLOS One. 7 (7): e41778. Bibcode:2012PLoSO...741778K. doi:10.1371/journal.pone.0041778. PMC 3408478. PMID 22860015.
222. Kirsch, I., Sapirstein, G (26 June 1998). "Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication". Prevention and Treatment. 1 (2): Article 0002a. doi:10.1037/1522-3736.1.1.12a. Archived from the original on 15 July 1998.
223. Kirsch I (2009). "Antidepressants and the placebo response". Epidemiol Psychiatr Soc. 18 (4): 318–22. doi:10.1017/s1121189x00000282. PMID 20170046. S2CID 2166423.
224. Preskorn SH, Ross R, Stanga CY (2004). "Selective Serotonin Reuptake Inhibitors". In Preskorn SH, Feighner HP, Stanga CY, Ross R (eds.). Antidepressants: Past, Present and Future. Berlin: Springer. pp. 241–62. ISBN 978-3-540-43054-4.
225. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. (January 2010). "Antidepressant drug effects and depression severity: a patient-level meta-analysis". JAMA. 303 (1): 47–53. doi:10.1001/jama.2009.1943. PMC 3712503. PMID 20051569.
226. Kramer P (7 September 2011). "In Defense of Antidepressants". The New York Times. Archived from the original on 12 July 2011. Retrieved 13 July 2011.
227. Pies R (April 2010). "Antidepressants work, sort of—our system of care does not". Journal of Clinical Psychopharmacology. 30 (2): 101–104. doi:10.1097/JCP.0b013e3181d52dea. PMID 20520282.
228. Pies RW (February 2016). "Antidepressants: Conundrums and Complexities of Efficacy Studies". Journal of Clinical Psychopharmacology. 36 (1): 1–4. doi:10.1097/jcp.0000000000000455. PMID 26658086. S2CID 28469650.
229. Cashman JR, Ghirmai S (October 2009). "Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression". Bioorganic & Medicinal Chemistry. 17 (19): 6890–6897. doi:10.1016/j.bmc.2009.08.025. PMID 19740668.
230. Goldenberg MM (November 2013). "Pharmaceutical approval update". P T. 38 (11): 705–7. PMC 3875258. PMID 24391391.
231. American Pharmacists Association (2013). "Vortioxetine: Atypical antidepressant". Archived from the original on 20 November 2015.
232. "FDA approves a new antidepressant: Brintellix". Los Angeles Times. 2013. Archived from the original on 20 November 2015.
233. Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology. 510 (1–2): 49–57. doi:10.1016/j.ejphar.2005.01.018. PMID 15740724.
234. Stahl SM (2013). Stahl's essential psychopharmacology : neuroscientific basis and practical application. with illustrations by Muntner N (4th ed.). Cambridge: Cambridge University Press. ISBN 978-1107686465.
235. ^ Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur J Pharmacol. 340 (2–3): 249–258. doi:10.1016/S0014-2999(97)01393-9. PMID 9537821.
236. Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.
237. Trindade E, Menon D, Topfer LA, Coloma C (November 1998). "Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis". CMAJ. 159 (10): 1245–1252. PMC 1229819. PMID 9861221.
238. Cristancho, Mario (20 November 2012). "Atypical Depression in the 21st Century: Diagnostic and Treatment Issues". Psychiatric Times. 28 (1). Archived from the original on 2 December 2013. Retrieved 23 November 2013.
239. Shulman KI, Herrmann N, Walker SE (October 2013). "Current place of monoamine oxidase inhibitors in the treatment of depression". CNS Drugs. 27 (10): 789–797. doi:10.1007/s40263-013-0097-3. PMID 23934742. S2CID 21625538.
240. Buigues J, Vallejo J (February 1987). "Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks". The Journal of Clinical Psychiatry. 48 (2): 55–59. PMID 3542985.
241. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. (April 1992). "Phenelzine vs atenolol in social phobia. A placebo-controlled comparison". Archives of General Psychiatry. 49 (4): 290–300. doi:10.1001/archpsyc.49.4.290. PMID 1558463.
242. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (September 1992). "Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine". The British Journal of Psychiatry. 161 (3): 353–360. doi:10.1192/bjp.161.3.353. PMID 1393304. S2CID 45341667.
243. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. (December 1998). "Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome". Archives of General Psychiatry. 55 (12): 1133–1141. doi:10.1001/archpsyc.55.12.1133. PMID 9862558.
244. Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC (May 1999). "Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial". Archives of General Psychiatry. 56 (5): 431–437. doi:10.1001/archpsyc.56.5.431. PMC 1475805. PMID 10232298.
245. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, et al. (July 1984). "Phenelzine v imipramine in atypical depression. A preliminary report". Archives of General Psychiatry. 41 (7): 669–677. doi:10.1001/archpsyc.1984.01790180039005. PMID 6375621.
246. Walsh BT, Stewart JW, Roose SP, Gladis M, Glassman AH (November 1984). "Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study". Archives of General Psychiatry. 41 (11): 1105–1109. doi:10.1001/archpsyc.1983.01790220095015. PMID 6388524.
247. Rothschild R, Quitkin HM, Quitkin FM, Stewart JW, Ocepek-Welikson K, McGrath PJ, et al. (January 1994). "A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives". The International Journal of Eating Disorders. 15 (1): 1–9. doi:10.1002/1098-108X(199401)15:1<1::AID-EAT2260150102>3.0.CO;2-E. PMID 8124322.
248. Walsh BT, Stewart JW, Roose SP, Gladis M, Glassman AH (1985). "A double-blind trial of phenelzine in bulimia". Journal of Psychiatric Research. 19 (2–3): 485–489. doi:10.1016/0022-3956(85)90058-5. PMID 3900362.
249. Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH (May 1988). "Phenelzine vs placebo in 50 patients with bulimia". Archives of General Psychiatry. 45 (5): 471–475. doi:10.1001/archpsyc.1988.01800290091011. PMID 3282482.
250. Davidson J, Walker JI, Kilts C (February 1987). "A pilot study of phenelzine in the treatment of post-traumatic stress disorder". The British Journal of Psychiatry. 150 (2): 252–255. doi:10.1192/bjp.150.2.252. PMID 3651684. S2CID 10001735.
251. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF (May 1993). "Efficacy of phenelzine and haloperidol in borderline personality disorder". Archives of General Psychiatry. 50 (5): 377–385. doi:10.1001/archpsyc.1993.01820170055007. PMID 8489326.
252. Mallinger AG, Frank E, Thase ME, Barwell MM, Diazgranados N, Luckenbaugh DA, et al. (2009). "Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?". Psychopharmacology Bulletin. 42 (2): 64–74. PMC 3570273. PMID 19629023.
253. Liebowitz MR, Hollander E, Schneier F, Campeas R, Welkowitz L, Hatterer J, et al. (1990). "Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders". Acta Psychiatrica Scandinavica. Supplementum. 360: 29–34. doi:10.1111/j.1600-0447.1990.tb05321.x. PMID 2248064. S2CID 30319319.
254. ^ "SPRAVATO™ (Esketamine) nasal spray FDA label" (PDF). Food and Drug Administration. 5 March 2019. Retrieved 6 March 2019.
255. Keam SJ (November 2022). "Dextromethorphan/Bupropion: First Approval". CNS Drugs. 36 (11): 1229–1238. doi:10.1007/s40263-022-00968-4. PMID 36301443. S2CID 253158902.
256. Parincu Z, Iosifescu DV (March 2023). "Combinations of dextromethorphan for the treatment of mood disorders – a review of the evidence". Expert Review of Neurotherapeutics. 23 (3): 205–212. doi:10.1080/14737175.2023.2192402. PMID 36943010. S2CID 257638827.
257. "Depressive Disorders". Merck Manual. Archived from the original on 5 December 2013. Retrieved 30 November 2012.
258. Taylor D, Carol P, Shitij K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97969-3.
259. Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, et al. (November 2014). "Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents" (PDF). The Cochrane Database of Systematic Reviews. 2014 (11): CD008324. doi:10.1002/14651858.CD008324.pub3. hdl:11343/59254. PMC 8556660. PMID 25433518. Archived (PDF) from the original on 9 October 2022.
260. Bauer M, Dopfmer S (1999). "Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies". Journal of Clinical Psychopharmacology. 19 (5): 427–34. doi:10.1097/00004714-199910000-00006. PMID 10505584. S2CID 31979046.
261. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ (March 2007). "Lithium treatment reduces suicide risk in recurrent major depressive disorder". J Clin Psychiatry. 68 (3): 380–83. doi:10.4088/JCP.v68n0304. PMID 17388706. S2CID 10343453.
262. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. (2006). "A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report". American Journal of Psychiatry. 163 (9): 1519–30. doi:10.1176/appi.ajp.163.9.1519. PMID 16946176.
263. Stahl SM (2011). The Prescriber's Guide (Stahl's Essential Psychopharmacology). Cambridge University Press. p. 39.
264. Kraus MF, Burch EA (October 1992). "Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review". Southern Medical Journal. 85 (10): 985–991. doi:10.1097/00007611-199210000-00012. PMID 1411740.
265. ^ Orr K, Taylor D (2007). "Psychostimulants in the treatment of depression : a review of the evidence". CNS Drugs. 21 (3): 239–257. doi:10.2165/00023210-200721030-00004. PMID 17338594. S2CID 35761979.
266. ^ Weber MM, Emrich HM (1988). "Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders". International Clinical Psychopharmacology. 3 (3): 255–66. doi:10.1097/00004850-198807000-00007. PMID 3153713.
267. Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol. 27 (6): 479–96. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
268. Czygan FC (2003). "Kulturgeschichte und Mystik des Johanniskrauts: Vom 2500 Jahre alten Apotropaikum zum aktuellen Antidepressivum" [From a 2500-year-old apotropic comes a current antidepressive. The cultural history and mistique of St. John's wort]. Pharmazie in unserer Zeit (in German). 32 (3): 184–90. doi:10.1002/pauz.200390062. PMID 12784538.
269. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (August 1996). "St John's wort for depression—an overview and meta-analysis of randomized clinical trials". The BMJ. 313 (7052): 253–258. doi:10.1136/bmj.313.7052.253. PMC 2351679. PMID 8704532.
270. Buettner C, Mukamal KJ, Gardiner P, Davis RB, Phillips RS, Mittleman MA (November 2009). "Herbal supplement use and blood lead levels of United States adults". Journal of General Internal Medicine. 24 (11): 1175–1182. doi:10.1007/s11606-009-1050-5. PMC 2771230. PMID 19575271.
271. Müller WE (February 2003). "Current St John's wort research from mode of action to clinical efficacy". Pharmacological Research. 47 (2): 101–109. doi:10.1016/S1043-6618(02)00266-9. PMID 12543057.
272. Nathan PJ (March 2001). "Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology". Journal of Psychopharmacology. 15 (1): 47–54. doi:10.1177/026988110101500109. PMID 11277608. S2CID 36924335.
273. Selikoff IJ, Robitzek EH (1952). "Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic Acid". Chest. 21 (4): 385–438. doi:10.1378/chest.21.4.385. PMID 14906149.
274. Healy D (2001). "The Antidepressant Drama". In Weissman MM (ed.). The treatment of depression: bridging the 21st century. American Psychiatric Pub. pp. 10–11. ISBN 978-0-88048-397-1.
275. Healy D (1996). The psychopharmacologists: interviews. London: Chapman and Hall. p. 8. ISBN 978-1-86036-008-4.
276. Healy D (1998). The Psychopharmacologists. Vol. 2. A Hodder Arnold Publication. pp. 132–4. ISBN 978-1-86036-010-7.
277. Robitzek EH, Selikoff IJ, Mamlok E, Tendlau A (1953). "Isoniazid and Its Isopropyl Derivative in the Therapy of Tuberculosis in Humans: Comparative Therapeutic and Toxicologic Properties". Chest. 23 (1): 1–15. doi:10.1378/chest.23.1.1. PMID 12998444.
278. ^ López-Muñoz F, Alamo C, Juckel G, Assion HJ (2007). "Half a Century of Antidepressant Drugs". Journal of Clinical Psychopharmacology. 27 (6): 555–9. doi:10.1097/jcp.0b013e3181bb617. PMID 18004120.
279. "Psychic Energizer". Time. 15 April 1957. Archived from the original on 11 August 2013. Retrieved 28 May 2009.
280. Kuhn R (1958). "The treatment of depressive states with G 22355 (Imipramine Hydrochloride)". The American Journal of Psychiatry. 115 (5): 459–64. doi:10.1176/ajp.115.5.459. PMID 13583250.
281. "Tranquilizers". Cumberland Mountain Community Services. cmcsb.com. Archived from the original on 16 September 2012. Retrieved 20 November 2013.
282. ^ Healy D (1999). "The Three Faces of the Antidepressants: A Critical Commentary on the Clinical-Economic Context of Diagnosis". The Journal of Nervous & Mental Disease. 187 (3): 174–80. doi:10.1097/00005053-199903000-00007. PMID 10086474.
283. Pletscher A (1991). "The discovery of antidepressants: A winding path". Experientia. 47 (1): 4–8. doi:10.1007/BF02041242. PMID 1999242. S2CID 112210.
284. Domino EF (1999). "History of modern psychopharmacology: A personal view with an emphasis on antidepressants". Psychosomatic Medicine. 61 (5): 591–8. doi:10.1097/00006842-199909000-00002. PMID 10511010.
285. Wong DT, Bymaster FP, Horng JS, Molloy BB (1975). "A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine". The Journal of Pharmacology and Experimental Therapeutics. 193 (3): 804–11. PMID 1151730. Archived from the original on 19 November 2021. Retrieved 24 April 2009.
286. Freeman H (1996). "Tolerability and safety of novel antidepressants". European Psychiatry. 11: 206s. doi:10.1016/0924-9338(96)88597-X. S2CID 144286291.
287. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. (March 2019). "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial". Psychological Medicine. 49 (4): 655–663. doi:10.1017/S0033291718001356. PMC 6378413. PMID 29903051.
288. de Araujo DB (15 February 2017). "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression – Full Text View – ClinicalTrials.gov". clinicaltrials.gov.
289. "FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder". businesswire.com. 22 November 2019. Retrieved 17 September 2020.
290. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. (July 2020). "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis". The Lancet. Psychiatry. 7 (7): 581–601. doi:10.1016/S2215-0366(20)30137-1. PMC 7303954. PMID 32563306.
291. Davis R (11 June 2010). "Antidepressant Use Rises as Recession Feeds Wave of Worry". The Guardian. London. Archived from the original on 15 June 2010. Retrieved 1 July 2010.
292. Spence R. "Focus on: Antidepressant prescribing". QualityWatch. QualityWatch (Nuffield Trust/Health Foundation). Archived from the original on 4 February 2015. Retrieved 12 January 2015.
293. "Teenagers' use of antidepressants is rising with variations across regions and ethnic groups". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 18 November 2020. doi:10.3310/alert_42239. S2CID 240759939.
294. Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, et al. (July 2020). Hellner C (ed.). "Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998–2017: A population-based cohort study". PLOS Medicine. 17 (7): e1003215. doi:10.1371/journal.pmed.1003215. PMC 7375537. PMID 32697803.
295. Robinson J (23 June 2021). "Peaks in number of young people prescribed antidepressants coincide with lockdowns". The Pharmaceutical Journal. Retrieved 4 November 2022.
296. Jack RH, Joseph RM, Coupland C, Butler D, Hollis C, Morriss R, et al. (April 2020). "Secondary care specialist visits made by children and young people prescribed antidepressants in primary care: a descriptive study using the QResearch database". BMC Medicine. 18 (1): 93. doi:10.1186/s12916-020-01560-7. PMC 7191694. PMID 32349753.
297. "GPs giving antidepressants to children against guidelines". The Guardian. 4 November 2022. Retrieved 5 November 2022.
298. Walkup JT, Strawn JR (May 2020). "High-quality antidepressant prescribing: please consider whether "perfection is the enemy of progress"". BMC Medicine. 18 (1): 150. doi:10.1186/s12916-020-01621-x. PMC 7243321. PMID 32438910.
299. ^ White R. "Waking up from sadness: Many find trouble getting off antidepressants". Al Jazeera. Archived from the original on 14 July 2014. Retrieved 8 June 2014.
300. "By the numbers: Antidepressant use on the rise". apa.org. Retrieved 1 February 2019.
301. "Top 200 generic drugs by units in 2010" (PDF). Archived from the original (PDF) on 15 December 2012."Top 200 brand drugs by units in 2010" (PDF). Archived from the original (PDF) on 22 April 2012.
302. "GIPdatabank". Gipdatabank.nl. Archived from the original on 6 December 2008. Retrieved 6 November 2008.
303. "Adherence to Long Term Therapies: Evidence for Action" (PDF). World Health Organization. 2003.
304. Kaplan JE, Keeley RD, Engel M, Emsermann C, Brody D (July 2013). "Aspects of patient and clinician language predict adherence to antidepressant medication". Journal of the American Board of Family Medicine. 26 (4): 409–420. doi:10.3122/jabfm.2013.04.120201. PMID 23833156.
305. Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA (March 2016). "Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review". Journal of Affective Disorders. 193: 1–10. doi:10.1016/j.jad.2015.12.029. PMID 26748881.
306. ^ Ecks S (2005). "Pharmaceutical Citizenship: Antidepressant Marketing and the Promise of Demarginalization in India". Anthropology & Medicine. 12 (3): 239–254. doi:10.1080/13648470500291360. PMID 26873669. S2CID 23046695.
307. ^ Lock M, Nguyen VK (2010). ""Local Biologies and Human Difference". An anthropology of biomedicine (1st ed.). Chichester, West Sussex: Wiley-Blackwell. pp. 83–109. ISBN 978-1-4051-1071-6.
308. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, et al. (2007). "LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake". Science. 317 (5843): 1390–3. Bibcode:2007Sci...317.1390Z. doi:10.1126/science.1147614. PMC 3711652. PMID 17690258.
309. Fong PP (2001). "Antidepressants in Aquatic Organisms: A Wide Range of Effects". In Daughton CG, Jones-Lepp TJ (eds.). Pharmaceuticals and personal care products in the environment: scientific and regulatory issues. Washington, DC: American Chemical Society. pp. 264–281. ISBN 978-0-8412-3739-1.
310. Brooks BW, Chambliss CK, Stanley JK, Ramirez A, Banks KE, Johnson RD, et al. (2005). "Determination of select antidepressants in fish from an effluent-dominated stream". Environ. Toxicol. Chem. 24 (2): 464–9. doi:10.1897/04-081r.1. PMID 15720009. S2CID 27420248.
311. Fent K, Weston AA, Caminada D (2006). "Ecotoxicology of human pharmaceuticals". Aquat. Toxicol. 76 (2): 122–59. Bibcode:2006AqTox..76..122F. doi:10.1016/j.aquatox.2005.09.009. PMID 16257063.
312. Winberg S, Carter CG, McCarthy JD, He XY, Nilsson GE, Houlihan DF (1993). "Feeding rank and brain serotonergic activity in rainbow trout Onchorhynchus my kiss". J. Exp. Biol. 179: 197–211. doi:10.1242/jeb.179.1.197.
313. Huber R, Smith K, Delago A, Isaksson K, Kravitz EA (1997). "Serotonin and aggressive motivation in crustaceans: altering the decision to retreat". Proc. Natl. Acad. Sci. U.S.A. 94 (11): 5939–42. Bibcode:1997PNAS...94.5939H. doi:10.1073/pnas.94.11.5939. PMC 20885. PMID 9159179.
314. Perreault HA, Semsar K, Godwin J (2003). "Fluoxetine treatment decreases territorial aggression in a coral reef fish". Physiol. Behav. 79 (4–5): 719–24. doi:10.1016/S0031-9384(03)00211-7. PMID 12954414. S2CID 39464936.
315. Di Poi C, Darmaillacq AS, Dickel L, Boulouard M, Bellanger C (2013). "Effects of perinatal exposure to waterborne Fluoxetine on memory processing in the cuttlefish Sepia officinalis". Aquat. Toxicol. 132–133: 84–91. Bibcode:2013AqTox.132...84D. doi:10.1016/j.aquatox.2013.02.004. PMID 23474317.
316. Hiemke C, Härtter S (January 2000). "Pharmacokinetics of selective serotonin reuptake inhibitors" (PDF). Pharmacology & Therapeutics. 85 (1): 11–28. doi:10.1016/s0163-7258(99)00048-0. PMID 10674711. Archived from the original (PDF) on 23 May 2014.
317. Nentwig G (February 2007). "Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug Fluoxetine". Archives of Environmental Contamination and Toxicology. 52 (2): 163–170. Bibcode:2007ArECT..52..163N. doi:10.1007/s00244-005-7190-7. PMID 17160491. S2CID 22309647.

Further reading

• Stahl SM (1997). Psychopharmacology of Antidepressants. Informa Healthcare. ISBN 978-1-85317-513-8.

External links

• Media related to Antidepressants at Wikimedia Commons

• Anaphrodisia
• Antidepressants
• Major depressive disorder
• Drug classes defined by psychological effects